UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 10-Q

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

	For the quarterly period ended March 31, 2024

	OR

☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

	For the transition period from ___________ to ___________

For the quarterly period ended September 30, 2023

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ______ to ______

Commission file number 000-15327

LadRx Corporation

(Exact name of registrant as specified in its charter)

Delaware		58-1642740
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

11726 San Vicente Blvd., Suite 650 Los Angeles, CA		90049
(Address of principal executive offices)		(Zip Code)

(310) 826-5648

(Registrant’s telephone number, including area code)

N/A

(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class Trading Symbol(s) Name of each exchange on which registered None None None

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.001 par value per share	LADX	OTC Markets
Series B Junior Participating Preferred Stock Purchase Rights

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company.. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐	Accelerated filer ☐	Non-accelerated filer ☒	Smaller reporting company ☒
Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Yes ☐ No ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

Number of shares of common stock of LadRx Corporation, $0.001 par value, outstanding as of ~~November~~May 14, ~~2023~~2024: 495,092 shares.

shares.

LADRX CORPORATION

FORM 10-Q

TABLE OF CONTENTS

		Page
PART I. — FINANCIAL INFORMATION		4
Item 1.	Condensed ~~Consolidated~~ Financial Statements (unaudited)	4
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	1814
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	2420
Item 4.	Controls and Procedures	2520
PART II. — OTHER INFORMATION		2521
Item 1.	Legal Proceedings	2521
Item 1A	Risk Factors	2521
Item 2	Unregistered Sales of Equity Securities and Use of Proceeds	2521
Item 3.	Defaults Upon Senior Securities	2521
Item 4	Mine Safety Disclosures	25
Item 4.	Mine Safety Disclosure	21
Item 5.	Other Information	2521
Item 6.	Exhibits	2521
SIGNATURES		2622
INDEX TO EXHIBITS		2723

Forward Looking Statements

All statements in this Quarterly Report on Form ~~10Q~~10-Q (this “~~Quarterly~~Qaurterly Report”), including statements in this section, other ~~than~~ than statements of historical fact are forward-looking statements, including statements of our current views with respect to the recent ~~developments~~ developments regarding our business strategy, business plan and research and development activities, our future financial results, and other future events. These statements include forward-looking statements both with respect to us, specifically, and the biotechnology industry, in general. In some cases, forward-looking statements can be identified by the use of terminology such as “may,” “will,” “expects,” “plans,” “anticipates,” “estimates,” “potential” or “could” or the negative thereof or other comparable terminology. Although we believe that the expectations reflected in the forward-looking statements contained herein are reasonable, there can be no assurance that such expectations or any of the forward-looking statements will prove to be correct, and actual results could differ materially from those projected or assumed in the forward-looking statements.

All forward-looking statements involve inherent risks and uncertainties, and there are or will be important factors that could cause actual results to differ materially from those indicated in these statements. We believe that these factors include, but are not limited to, the factors discussed in this section and under the caption “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, ~~2022~~2023 (the “2023 Annual Report”), which should be reviewed carefully. If one or more of these or other ~~risks~~ risks or uncertainties materialize, or if our underlying assumptions prove to be incorrect, actual results may vary materially from what we we anticipate. Please consider our forward-looking statements in light of those risks as you read this Quarterly Report. We undertake no no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or or otherwise.

Note Regarding Company References

References throughout this Quarterly Report, the “Company”, “LadRx”, “we”, “us”, and “our”, except where the context requires otherwise, refer to LadRx Corporation ~~and its subsidiary~~.

PART I — FINANCIAL INFORMATION

Item 1. — Condensed ~~Consolidated~~ Financial Statements

LADRX CORPORATION ~~CONDENSED CONSOLIDATED BALANCE SHEETS~~

	September 30, 2023			December 31, 2022
ASSETS	(Unaudited)
Current assets:
Cash and cash equivalents	$	2,933,410		$	1,374,992
Prepaid expenses and other current assets		36,233			628,745
Total current assets		2,969,643			2,003,737
Equipment and furnishings, net		9,670			18,546
Other assets		7,703			7,703
Operating lease right-of-use assets		78,550			216,786
Total assets	$	3,065,566		$	2,246,772
LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)
Current liabilities:
Accounts payable	$	987,023		$	975,944
Accrued expenses and other current liabilities		1,029,623			1,015,501
Current portion of operating lease liabilities		83,530			196,081
Total current liabilities		2,100,176			2,187,526
Operating lease liabilities, net of current portion		—			33,526
Total Liabilities		2,100,176			2,221,052
Preferred Stock, Series C 10% Convertible, $1,000 par value, 0 and 2,752 shares issued and outstanding at September 30, 2023 and December 31, 2022, respectively		—			1,343,684
Commitments and contingencies		-			-
Stockholders’ equity (deficit):
Preferred Stock, $0.01 par value, 833,333 shares authorized, including 50,000 shares of Series B Junior Participating Preferred Stock; no shares issued and outstanding		—			—
Common stock, $0.001 par value, 62,393,940 shares authorized, 495,092 and 450,374 shares issued and outstanding at September 30, 2023 and December 31, 2022, respectively		495			450
Additional paid-in capital		488,612,890			487,519,251
Accumulated deficit		(487,647,995	)		(488,837,665	)
Total stockholders’ equity (deficit)		965,390			(1,317,964	)
Total liabilities and stockholders’ equity (deficit)	$	3,065,566		$	2,246,772

CONDENSED BALANCE SHEETS

The accompanying notes are an integral part of these condensed consolidated financial statements.

	March 31, 2024			December 31, 2023
	(Unaudited)
ASSETS
Current assets:
Cash and cash equivalents	$	2,064,191		$	2,070,075
Prepaid expenses and other current assets		150,958			191,783
Total current assets		2,215,149			2,261,858
Equipment and furnishings, net		4,650			6,711
Other assets		1,475			7,703
Operating lease right-of-use assets		—			31,610
Total assets	$	2,221,274		$	2,307,882
LIABILITIES AND STOCKHOLDERS’ EQUITY

Current liabilities:
Accounts payable	$	892,192		$	1,202,689
Accrued expenses and other current liabilities		983,874			964,233
Current portion of operating lease liabilities		—			33,606
Total current liabilities		1,876,066			2,200,528

Commitments and contingencies		-			-

Stockholders’ equity:
Preferred Stock, $0.01 par value, 833,333 shares authorized, including 50,000 shares of Series B Junior Participating Preferred Stock; no shares issued and outstanding		—			—
Common stock, $0.001 par value, 62,393,940 shares authorized; 495,092 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively		495			495
Additional paid-in capital		488,664,009			488,612,890
Accumulated deficit		(488,319,296	)		(488,506,031	)
Total stockholders’ equity		345,208			107,354
Total liabilities and stockholders’ equity	$	2,221,274		$	2,307,882

The accompanying notes are an integral part of these condensed financial statements.

LADRX CORPORATION

CONDENSED ~~CONSOLIDATED~~ STATEMENTS OF OPERATIONS

(Unaudited)

	2023			2022			2023			2022
	Three Months Ended March 31,
	Three Months Ended September 30,						Nine Months Ended September 30,
	2024			2023
	2023			2022			2023			2022
Revenue:
Revenue:
Licensing revenue	$	—		$	—
Licensing revenue	$	—		$	—		$	—		$	—
Expenses:
Expenses:
Research and development		30,296			—
Research and development		14,625			—			14,625			—
General and administrative		801,601			1,080,039
General and administrative		825,688			1,167,527			2,926,892			3,610,172
Loss from operations		(831,897	)		(1,080,039	)
Loss from operations		(840,313	)		(1,167,527	)		(2,941,517	)		(3,610,172	)
Other income:
Other income (loss):
Interest income		18,632			4,267
Interest income		24,307			789			31,405			2,643
Royalty and milestone rights		1,000,000			—
Forgiveness of accounts payable		—			—			—			353,565
Other income, net		—			1,274
Sale of royalty and milestone rights, net of transaction costs		—						4,167,219
Net income (loss)	$	186,735		$	(1,074,498	)
Other income (loss), net		17			59			1,372			(2,402	)
Dividends paid on preferred shares		—			(68,809	)
Net income (loss)	$	(815,989	)	$	(1,166,679	)	$	1,258,479		$	(3,256,366	)
Net income (loss) attributable to common stockholders	$	186,735		$	(1,143,307	)
Dividends paid on preferred shares		—			(84,005	)		(68,809	)		(492,572	)
Total basic and diluted income (loss) per share	$	0.38		$	(0.03	)
Net income (loss) attributable to common stockholders	$	(815,989	)	$	(1,250,684	)	$	1,189,670		$	(3,748,938	)
Basic and diluted weighted-average shares outstanding		495,092			460,790
Total basic and diluted income (loss) per share	$	(1.65	)	$	(2.78	)	$	2.59		$	(8.76	)
Basic and diluted weighted-average shares outstanding		495,092			450,373			486,101			428,027

The accompanying notes are an integral part of these condensed ~~consolidated~~ financial statements

LADRX CORPORATION

CONDENSED ~~CONSOLIDATED~~ STATEMENTS OF CASH FLOWS

(Unaudited)

	2023			2022
	Three Months Ended March 31,
	Nine Months Ended September 30,
	2024			2023
	2023			2022
Cash flows from operating activities:
Net income (loss)	$	1186,~~258,479~~735		$	(31,~~256~~074,~~366~~498	)
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Depreciation and amortization		82,~~876~~060			112,~~248~~958
Stock-based compensation expense		—51,119			~~8,940~~—
Changes in assets and liabilities:
Insurance claim receivable		—			200,000
Prepaid expenses and other current assets		40,825			199,102
Prepaid expenses and other current assets		592,511			1,238,994
Other assets		6,228			—
Other assets		—			9,133
Right-of-use asset		31,610			45,654
Amortization of right-of-use asset		138,236			135,141
Accounts payable		(310,497	)		150,347
Accounts payable		11,079			(567,512	)
Decrease in lease liabilities		(33,605	)		(47,529	)
Decrease in lease liabilities		(146,078	)		(139,028	)
Accrued expenses and other current liabilities		19,641			24,156
Accrued expenses and other current liabilities		14,124			(901,101	)
Net cash used in operating activities		(5,884	)		(699,810	)
Net cash provided by (used in) operating activities		1,877,227			(3,260,551	)
Cash flows from investing activities:
Purchase of fixed assets		—			(766	)
Net cash used in investing activities		—			(766	)
Cash flows from financing activities
Preferred stock dividend		~~(68,809~~—	)		(~~492~~68,~~572~~809	)
Purchase of preferred investment option		(250,000	)		—
Net cash used in financing activities		—			(68,809	)
Net cash used in financing activities		(318,809	)		(492,572	)
Net decrease in cash and cash equivalents		(5,884	)		(768,619	)
Net increase (decrease) in cash and cash equivalents		1,558,418			(3,753,889	)
Cash and cash equivalents at beginning of period		2,070,075			1,374,992
Cash and cash equivalents at beginning of period		1,374,992			6,769,603
Cash and cash equivalents at end of period	$	2,064,191		$	606,373
Cash and cash equivalents at end of period	$	2,933,410		$	3,015,714
Supplemental disclosure of Cash Flow Information:
Conversion of Series C 10% Convertible Preferred Stock to Common Stock	$	1,343,684		$	2,679,019
Conversion of Series C Preferred Stock to Common Stock	$	—		$	2,011,351

The accompanying notes are an integral part of these condensed ~~consolidated~~ financial statements

LADRX CORPORATION

CONDENSED ~~CONSOLIDATED~~ STATEMENTS OF STOCKHOLDERS’ EQUITY (DEFICIT)

(Unaudited)

For the ~~Nine~~ Three-Month Period Ended ~~September~~March 3031, ~~2023~~2024

	Series B Preferred Shares Issued			Common Shares Issued		Common Stock Amount		Additional Paid-in Capital			Accumulated Deficit			Total
	Common Shares Issued			Common Stock Amount		Additional Paid-in Capital		Accumulated Deficit			Total
Balance at January 1, 2023		—	-		450,374	$	450	$	487,519,251		$	(488,837,665	)	$	(1,317,964	)
Balance at January 1, 2024		495,092			495	$	488,612,890	$	(488,506,031	)	$	107,354
1-100 Reverse stock split fractional shares					13,191		13		(13	)					—
Issuance of stock options for compensation							51,119					51,119
Issuance of common stock		-			250		1		(1	)					—
Net income		-			-		-		186,735			186,735
Conversion of preferred shares					15,250		15		655,139						655,154
									-			-
Preferred dividend												(68,809	)		(68,809	)
Balance at March 31, 2024		495,092		$	495	$	488,664,009	$	(488,319,296	)	$	345,208
Net loss		-	-		-		-		-			(1,074,498	)		(1,074,498	)
Balance at March 31, 2023		—	-		479,065	$	479	$	488,174,376		$	(489,980,972	)	$	(1,806,117	)
Conversion of preferred shares					16,027		16		688,514						688,530
Payment to redeem investment option									(250,000	)					(250,000	)
Net income		-	-		-		-		-			3,148,966			3,148,966
Balance at June 30, 2023		-	-		495,092	$	495	$	488,612,890		$	(486,832,006	)		1,781,379
Net loss		-	-		-		-		-			(815,989	)		(815,989	)
Balance at September 30, 2023		-	-		495,092	$	495	$	488,612,890		$	(487,647,995	)	$	965,390

For the ~~Nine~~ Three-Month Period Ended ~~September~~March 3031, ~~2022~~2023

	Series B Preferred Shares Issued			Common Shares Issued		Common Stock Amount			Additional Paid-in Capital			Accumulated Deficit			Total
	Common Shares Issued			Common Stock Amount		Additional Paid-in Capital			Accumulated Deficit			Total
Balance at January 1, 2022		—	-		387,800	$	388		$	484,829,042		$	(484,075,711	)	$	753,719
Balance at January 1, 2023		450,374		$	450	$	487,519,251		$	(488,837,665	)	$	(1,317,964	)
Balance		—450,374		$	~~387,800~~450	$	~~388~~487,519,251		$	~~484~~(488,~~829~~837,~~042~~665	)	$	(~~484~~1,~~075~~317,~~711~~964	)	$	~~753,719~~
Exercise of stock options					214											—
1-100 reverse split fractional shares		13,191			13		(13	)
Conversion of preferred shares					46,819		47			2,011,304						2,011,351
Preferred dividend										(68,809	)		(68,809	)
Preferred dividend													(206,000	)		(206,000	)
Conversion of Series C Convertible Preferred Stock		15,250			15		655,139			—			655,154
Issuance of restricted stock for compensation										3,299						3,299
Issuance of common stock		250			1		(1	)
Net loss		-	-		-		-			-(1,074,498	)		(1,~~295~~074,~~911~~498	)		~~(1,295,911~~	)
Balance at March 31, 2022		—	-		434,833	$	435		$	486,843,645		($	485,577,622	)	$	1,266,458
Net income (loss)										(1,074,498	)		(1,074,498	)
Conversion of preferred shares					15,541		15			667,653						667,668
Balance at March 31, 2023		479,065		$	479	$	488,174,376		$	(489,980,972	)	$	(1,806,117	)
Preferred dividend													(202,567	)		(202,567	)
Balance		479,065		$	479	$	488,174,376		$	(489,980,972	)	$	(1,806,117	)
Issuance of restricted stock for compensation										2,805						2,805
Net loss		-	-		-		-			-			(793,776	)		(793,776	)
Balance at June 30, 2022		—	-		450,374	$	450		$	487,514,103		$	(486,573,965	)	$	940,588
Balance		—			450,374	$	450		$	487,514,103		$	(486,573,965	)	$	940,588
Preferred dividend													(84,005	)		(84,005	)
Issuance of restricted stock for compensation										2,836						2,836
Net loss		-	-		-		-			-			(1,166,679	)		(1,166,679	)
Net income (loss)		-			-		-			-			(1,166,679	)		(1,166,679	)
Balance at September 30, 2022		-	-		450,374	$	450		$	487,516,939		$	(487,824,649	)	$	(307,260	)
Balance		-	-		450,374	$	450		$	487,516,939		$	(487,824,649	)	$	(307,260	)

The accompanying notes are an integral part of these condensed financial statements

LADRX CORPORATION

NOTES TO CONDENSED ~~CONSOLIDATED~~ FINANCIAL STATEMENTS

For the ~~Nine~~Three-Months Period Ended ~~September~~March 3031, ~~2023~~2024 and ~~2022~~2023 (Unaudited)

1. Basis of Presentation and Significant Accounting Policies

Basis of Presentation ~~and Principles of Consolidation~~

The accompanying condensed ~~consolidated~~ financial statements at ~~September~~March 3031, ~~2023~~2024 and for the three-month ~~and nine-month~~ periods ended ~~September~~ 30March 31, ~~2023~~2024 and ~~2022~~2023, respectively, are unaudited, but include all adjustments, consisting of normal recurring entries, that management believes to be necessary for a fair presentation of the periods presented. Interim results are not necessarily indicative of results for ~~the~~a full year ~~ending December 31, 2023~~. Balance sheet amounts as of December 31, ~~2022~~2023 were derived from our audited financial statements as of that date.

The ~~consolidated~~ financial statements included herein have been prepared by us pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted pursuant to such rules and regulations. The ~~consolidated~~ financial statements should be read in conjunction with our audited ~~consolidated~~ financial statements contained in the ~~2022~~2023 Annual Report.

Change in Company Name

Effective September 26, 2022, the Company changed its name from CytRx Corporation to LadRx Corporation pursuant to a Certificate of Amendment to our Certificate of Incorporation filed with the Secretary of State of Delaware. In accordance with the General Corporation Law of the State of Delaware (the “DGCL”), its board of directors approved the name change and the Certificate of Amendment. Pursuant to Section 242(b)(1) of the DGCL, stockholder approval was not required for the name change or the Certificate of Amendment.

Reverse Stock Split

The Company effected a 1-for-100 reverse stock split (the “Reverse Stock Split”) of its issued and outstanding shares of common stock on May 17, 2023, pursuant to which every 100 shares of the Company’s issued and outstanding shares of common stock were converted into one share of common stock without any change in the par value per share. Any fraction of a share of common stock that would otherwise have resulted from the Reverse Stock Split ~~were~~was rounded up to the nearest whole share. All share and per share amounts in ~~the~~this ~~accompanying~~Quarterly ~~financial~~Report ~~statements~~ have been adjusted to reflect the Reverse Stock Split as if it had occurred at the beginning of the earliest period presented.

Going Concern

The Company’s condensed ~~consolidated~~ financial statements have been presented on the basis that it will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. During the ~~nine~~three-month ~~months~~ period ended ~~September 30~~March 31, ~~2023~~2024, although ~~the~~we ~~Company~~ realized a net income of $10.2 million,~~258,479,~~ itwe had a loss from operations of $20.8 million,~~941,517~~ and ~~had an~~incurred ~~accumulated~~a ~~deficit~~net loss from operations of $~~487~~3.8 million for the year ended December 31,~~647~~ 2023,~~995~~ and had total stockholders’ equity as of ~~September~~March 3031, ~~2023.~~2024 Inof ~~addition,~~$0.3 million. ~~the~~The Company has no recurring revenue, and we are likely to continue to incur losses unless and until we conclude a successful strategic partnership or financing for our LADR™ technology. As a result, management has concluded that there is substantial doubt about the Company’s ability to continue as a going concern. The Company’s ~~consolidated~~ financial statements do not include any adjustments that might result from the outcome of this uncertainty. The Company’s independent registered public accounting firm, in its report on the Company’s consolidated financial statements for the year ended December 31, ~~2022~~2023, has also expressed ~~substantial~~ doubt about the Company’s ability to continue as a going concern.

At ~~September~~March 3031, ~~2023~~2024, we had cash and cash equivalents ~~and short-term investments~~ of approximately $2.91 million. We believe we have sufficient cash to fund operations into the summer of 2024. The continuation of the Company as a going concern is dependent upon its ability to obtain necessary debt or equity financing to continue operations until it begins generating positive cash flow. No assurance can be given that any future financing will be available or, if available, that it will be on terms that are satisfactory to the Company. Even if the Company is able to obtain additional financing, it may contain undue restrictions on our operations, in the case of debt financing or cause substantial dilution for our stockholders, in case orof equity financing.

Use of Estimates

Preparation of the Company’s condensed ~~consolidated~~ financial statements in conformance with U.S. GAAP requires the Company’s management to make estimates and assumptions that impact the reported amounts of assets, liabilities, revenues and expenses, and the disclosure of contingent assets and liabilities in the Company’s condensed ~~consolidated~~ financial statements and accompanying notes. The significant estimates in the Company’s condensed ~~consolidated~~ financial statements relate to the valuation of equity awards, recoverability of deferred tax assets, and estimated useful lives of fixed assets., The Company bases estimates and assumptions on historical experience, when available, and on various factors that it believes to be reasonable under the circumstances. The Company evaluates its estimates and assumptions on an ongoing basis, and its actual results may differ from estimates made under different assumptions or conditions.

Stock Compensation

The Company accounts for share-based awards to employees and ~~nonemployees~~non-employee directors and consultants in accordance with the provisions of ASC 718, Compensation—Stock Compensation., and under the recently issued guidance following FASB’s pronouncement, ASU 2018-07, Compensation—Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting. Under ASC 718, and applicable updates adopted, share-based awards are valued at fair value on the date of grant and that fair value is recognized over the requisite service, or vesting, period. The Company values its equity awards using the Black-Scholes option pricing model, and accounts for forfeitures when they occur.

Basic and Diluted Net Income (Loss) Per Common Share

Basic and diluted net income (loss) per common share is computed based on the weighted-average number of common shares outstanding. for the period. Diluted net income (loss) per share is computed by dividing the net income (loss) applicable to common stockholders by the weighted average number of common shares outstanding plus the number of additional common shares that would have been outstanding if all dilutive potential common shares had been issued using the treasury stock method. Potential common shares are excluded from the computation when their effect is antidilutive. Common share equivalents that could potentially dilute net loss per share in the future, and which were excluded from the computation of diluted loss per share, were as follows:

	2023		2022
	2024		2023
	As of September 30,
	As of March 31,
	2023		2022
	2024		2023
Options to acquire common stock		1568,~~647~~997		1817,~~477~~651
Warrants to acquire common stock		42—		42
Series C 10% Convertible Preferred Stock		—		31,272
Series C Convertible Preferred Stock		—		160,228
Preferred Investment Option		—		~~113~~1,~~637~~136,364
Share excluded from computation of diluted loss per shares		1568,~~689~~997		~~163~~1,~~428~~314,285

Fair Value Measurements

Assets and liabilities recorded at fair value on the balance sheets are categorized based upon the level of judgment associated with the inputs used to measure the fair value. Level inputs are as follows:

Level 1 – quoted prices in active markets for identical assets or liabilities.

Level 2 – other significant observable inputs for the assets or liabilities through corroboration with market data at the measurement date.

Level 3 – significant unobservable inputs that reflect management’s best estimate of what market participants would use to price the assets or liabilities at the measurement date.

We consider carrying amounts of accounts receivable, accounts payable and accrued expenses to approximate fair value due to the short-term nature of these financial instruments. Our non-financial assets are measured at fair value when there is an indicator of impairment and recorded at fair value only when an impairment charge is recognized.

Recently Issued Accounting Pronouncements

InRecent ~~June~~authoritative ~~2016,~~guidance ~~the FASB~~ issued ~~ASU~~by ~~No.~~the ~~2016-13,~~FASB ~~Credit Losses - Measurement of Credit Losses on Financial Instruments~~ (~~“ASU 2016-13”). The standard significantly changes how entities will measure credit losses for most financial assets,~~ including ~~accounts~~technical ~~and~~corrections ~~notes~~to ~~receivable. The~~the ~~standard will replace today’s “incurred loss” approach with an “expected loss” model~~ASC), ~~under which companies will recognize allowances based on expected rather than incurred losses. Entities will apply~~ the ~~standard’s~~American ~~provisions~~Institute ~~as a cumulative-effect adjustment to retained earnings as~~ of ~~the~~Certified ~~beginning~~Public ~~of the first reporting period in which the guidance is effective. The standard is~~Accountants, ~~effective for interim~~ and ~~annual~~the ~~reporting~~SEC ~~periods~~did ~~beginning after December 15~~not, ~~2022.~~or ~~The~~are ~~adoption~~not ofexpected ~~ASU~~to, ~~2016-13 did not~~ have a material impact on the Company’s consolidated financial ~~position,~~statements ~~results of operations,~~ and ~~cash flows~~related disclosures.

Other recent authoritative guidance issued by the FASB (including technical corrections to the ASC), the American Institute of Certified Public Accountants, and the SEC did not, or are not expected to, have a material impact on the Company’s condensed consolidated financial statements and related disclosures.

2. Financing Under Securities Purchase Agreement

On July 13, 2021, the Company entered into a Securities Purchase Agreement (the “Purchase Agreement”) with a single institutional investor (the “Investor”) for aggregate gross proceeds of $10 million and net proceeds of approximately $9.2 million. The transaction closed on July 16, 2021. Under the Purchase Agreement, the Company sold and issued (i) 20,000 shares of its common stock at a purchase price of $88.00 per share for total gross proceeds of approximately $1.76 million in a registered direct offering (the “Registered Direct Offering”) and (ii) 8,240 shares of Series C 10.00% Convertible Preferred Stock (the “Series C Preferred Stock”) at a purchase price of $1,000 per share, for aggregate gross proceeds of approximately $8.24 million, in a concurrent private placement (the “Private Placement” and, together with the Registered Direct Offering, the “July 2021 Offerings”). The shares of the Series C Preferred Stock were convertible, upon shareholder approval as described below, into an aggregate of up to 93,637 shares of common stock at a conversion price of $88.00 per share. Holders of the Series C Preferred Stock were entitled to receive, cumulative dividends at the rate per share (as a percentage of the stated value per share) of 10.00% per annum, payable quarterly on January 1, April 1, July 1 and October 1, beginning on the first such date after the date of issuance. The terms of the Series C Preferred Stock included beneficial ownership limitations that preclude conversion that would result in the Investor owning in excess of 9.99% of the Company’s outstanding shares of common stock. LadRx also issued to the Investor an unregistered Preferred Investment Option (“PIO”) that prior to redemption and cancelation of the PIO on June 29, 2023 (as described herein) allowed for the purchase of up to 113,637 shares of common stock for additional gross proceeds of approximately $10 million if the PIO was exercised in full. The exercise price for the PIO was $88.00 per share. The PIO had a term equal to five and one-half years commencing upon the Company increasing its authorized common stock following shareholder approval.

The Company accounted for these transactions as a single transaction for accounting purposes and allocated total proceeds to the respective instruments based upon the relative fair value of each instrument. The Company determined that the relative fair value of (i) the 20,000 shares of the common stock issued was $859,218, (ii) the relative fair value of the 8,240 shares of Series C Preferred Stock was $4,022,700, and (iii) the relative fair value of the PIO was $4,293,872 based upon a Black Scholes valuation model. As such, the Company recorded as Additional Paid in Capital the fair value of the common stock and PIO of $5,153,090, and the fair value of the Series C Preferred Stock was $4,022,700 which was reflected as mezzanine equity due to certain clauses of the Purchase Agreement.9

In 2022, the Company paid the following dividends: on January 1, 2022, $206,000, on April 1, 2022, $202,567, on July 1, 2022, $84,005 and on October 1, 2022, $68,809 for a total of $561,381. On January 3, 2023, the Company paid a dividend of $68,809.

~~On March~~At 15December 31, 2022, the atCompany ahad ~~special~~2,752 ~~meeting~~shares of ~~its~~Series ~~stockholders~~C ~~which~~Preferred ~~was~~Stock ~~originally~~outstanding. ~~opened~~On ~~and~~January ~~subsequently adjourned on September 23~~31, ~~2021~~2023, the ~~Company’s~~Investor ~~stockholders,~~converted bya anfurther ~~affirmative~~1,342 ~~vote~~ shares of ~~the~~Series ~~majority~~C ofPreferred ~~the~~Stock ~~Company’s~~for ~~outstanding~~15,250 shares of ~~capital~~common stock~~, approved~~ ~~the~~and ~~amendment~~on toMay ~~the~~8, ~~Company’s~~2023, ~~Restated~~the ~~Certificate~~Investor ofconverted ~~Incorporation~~its toremaining ~~effect~~shares anof ~~increase~~Series inC ~~the~~Preferred ~~number~~Shares offor ~~shares~~16,027 ofshares ~~authorized~~of common stock~~, par value $0~~.~~001~~ ~~per~~As ~~share,~~of ~~from~~March 4131,~~666,666~~ ~~shares~~2024 toand 62December 31,~~393,940~~ ~~shares~~2023, ~~and~~there towere ~~make~~no ~~a corresponding change~~shares ~~to the number~~ of ~~authorized~~Series ~~shares~~C ofPreferred ~~capital~~Stock ~~stock~~issued inand ~~order to comply with the Company’s contractual obligations under the Purchase Agreement~~outstanding.

~~On March 28, 2022, the Investor converted 4,120 shares of the Series C Preferred Stock in accordance with the initial terms of the agreement and received 46,818 shares of common shares~~3. ~~On May 15, 2022, the Investor converted a further 1,368 shares of the Series C Preferred~~ Stock ~~and~~Based received 15,541 shares of common shares, resulting in 2,742 shares of common stock outstanding at December 31, 2022. On January 31, 2023, the Investor converted a further 1,342 shares of Series C Preferred Stock for 15,250 shares of common stock and on May 8, 2023, the Investor converted its remaining shares of Series C Preferred Shares for 16,027 shares of common stock. As of September 30, 2023, there were no shares of Series C Preferred Stock issued and outstanding.Compensation

The Company has the 2008 Stock Incentive Plan(the “2008 Plan”) under which 50,000 shares of common stock are reserved for issuance. As of March 31, 2024, there were 10,500 shares subject to outstanding stock options and approximately 8,000 shares outstanding related to restricted stock grants issued from the 2008 Plan. This plan expired on November 20, 2018 and thus no further shares are available for future grant under this plan.

In November 2019, the Company adopted the 2019 Stock Incentive Plan (the “2019 Plan”) under which 54,000 shares of common stock are reserved for issuance. As of March 31, 2024, there were 3,500 shares subject to outstanding stock options and 250 shares outstanding related to restricted stock grants from the 2019 Plan. This Plan expires on November 14, 2029.

On September 7, 2023, the Board approved the first amendment (the “Plan Amendment”) to the 2019 Plan, effective as of the same date. The Plan Amendment amends the 2019 Plan to (i) reflect the Company’s recent name change from CytRx Corporation to LadRx Corporation, and (ii) increase the aggregate number of shares of common stock that may be issued under the 2019 Plan, as set forth in Section 4(a) of the 2019 Plan, by an additional 75,000 shares of common stock. On September 7, 2023, the Board additionally approved and set January 16, 2024, as the grant date for certain stock options to purchase shares of common stock to certain directors and officers of the Company, which such options to purchase up to a total of 55,000 shares of common stock were granted to employees and directors. Fifty percent of these options were immediately vested, and the remaining balance will vest in equal installments on a monthly basis over three years. There were no options issued in the period ended March 31, 2023.

The fair value of the stock options at the date of grant was estimated using the Black-Scholes option-pricing model, based on the following assumptions:

	2024			2023
Risk-free interest rate		3.52	%		2.42	%
Expected volatility		134	%		92	%
Expected lives (years)		6			6
Expected dividend yield		0.00	%		0.00	%

~~Terms~~The Company’s computation of ~~Series~~expected Cvolatility ~~Preferred~~is ~~Stock~~based on the historical daily volatility of its publicly traded stock. For option grants issued during years ended December 31, 2024, the Company used a calculated volatility for each grant. The Company lacks adequate information about the exercise behavior at this time and has determined the expected term assumption under the simplified method provided for under ASC 718, which averages the contractual term of the Company’s options of ten years with the average vesting term of three years for an average of six years. In 2024, the Company used the average term of six years. The dividend yield assumption of zero is based upon the fact the Company has never paid cash dividends on common stock and presently has no intention of paying cash dividends. The risk-free interest rate used for each grant is equal to the U.S. Treasury rates in effect at the time of the grant for instruments with a similar expected life. The Company accounts for forfeitures as they occur. No amounts relating to stock-based compensation have been capitalized. No amounts relating to employee stock-based compensation have been capitalized.

~~Under~~During the ~~Certificate~~three ofmonths ~~the~~ended ~~Designations,~~March ~~Powers~~31, ~~Preferences~~2024 and ~~Rights~~March ~~of Series C 10.00% Convertible Preferred Stock (the “Certificate of Designations”)~~31, ~~each share of Series C Preferred Stock was convertible~~2023, ~~subject~~no tooptions ~~the~~were Beneficial Ownership Limitation (as defined below), at either the holder’s option or at the Company’s option (a “Company Initiated Conversion”) at any time following stockholder approval having been obtained to amend our Restated Certificate of Incorporation to increase the number of authorized shares of common stock above 41,666,666 (the “Stockholder Approval”), into common stock at a conversion rate equal to the quotient of (i) the Series C Stated Value of $1,000 (the “Series C Stated Value”) plus, in the case of a Company initiated conversion, all accrued and accumulated and unpaid dividends on such share of Series C Preferred Stock, divided by (ii) the initial conversion price of $0exercised.~~88, subject to specified adjustments for stock splits, stock dividends, reclassifications or other similar events as set forth in the Certificate of Designations.~~

The Certificate of Designations contains limitations that prevent the holder thereof from acquiring shares of common stock upon conversion that would result in the number of shares of common stock beneficially owned by such holder and its affiliates exceeding 9.99% of the total number of shares of common stock outstanding immediately after giving effect to the conversion (the “Beneficial Ownership Limitation”), except that upon notice from the holder to the Company, the holder may increase or decrease the amount of ownership of outstanding shares of common stock after converting the holder’s shares of Series C Preferred Stock, provided that the Beneficial Ownership Limitation in no event exceeds 9.99% of the number of outstanding shares of the common stock outstanding immediately after giving effect to the issuance of shares of common stock upon conversion of the shares of Series C Preferred Stock held by the holder and provided that any increase in the Beneficial Ownership Limitation shall not be effective until 61 days following notice to the Company.

Each holder of shares of Series C Preferred Stock was entitled to receive dividends, commencing from the date of issuance of the shares of Series C Preferred Stock. Such dividends may be paid only when, as and if declared by the Board of Directors of the Company (the “Board”), out of assets legally available therefore, quarterly in arrears on the first day of January, April, July and October in each year, commencing on the date of issuance, at the dividend rate of 10.00% per year. Such dividends are cumulative and continue to accrue on a daily basis whether or not declared and whether or not we have assets legally available therefore.

Terms of Preferred Investment Option

Prior to the redemption and cancelation of the PIO on June 29, 2023,the PIO to purchase up to 113,637 shares of common stock was exercisable at a price of $88.00 per share. The PIO had a term of five and one-half years from the Authorized Share Increase Date. The holders of the PIO were able to exercise the PIO on a cashless basis, solely to the extent there was no effective registration statement registering, or the prospectus in such registration statement was not available for the resale of the shares of common stock issuable at the time of exercise. The Company was prohibited from effecting an exercise of any PIO to the extent that such exercise would result in the number of shares of common stock beneficially owned by such holder and its affiliates exceeding 9.99% of the total number of shares of common stock outstanding immediately after giving effect to the exercise of the PIO by the Investor (the “PIO Beneficial Ownership Limitation”), except that upon notice from the holder to the Company, the holder may increase or decrease the amount of ownership of outstanding shares of Common Stock after exercising the holder’s PIO, provided that the PIO Beneficial Ownership Limitation in no event exceeded 9.99% of the number of outstanding shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of common stock upon exercise of the PIO held by the holder and provided that any increase in the PIO Beneficial Ownership Limitation shall not be effective until 61 days following notice to the Company. The PIO provided for a Black-Scholes payout upon certain fundamental change transactions relating to the Company, as specified therein. If the fundamental change transaction was within the control of the Company, the payout would have been payable in cash. Otherwise, the payout would have been in the same form of consideration received by the common stockholders as a result of this transaction.

Redemption of Preferred Investment Option

On June 29, 2023 (the Redemption Date”), the Company entered into a Preferred Investment Option Redemption Agreement (the “Redemption Agreement”) with the Investor in connection with the PIO. As of the Redemption Date and pursuant to the Redemption Agreement, as complete and full consideration for the assignment, transfer, conveyance, delivery and relinquishment of the Investor’s right, title and interest in and to the PIO, the Company made a cash payment of $250,000 to the Investor. The Investor and the Company also executed a general release of any and all claims, demands, damages, liabilities, obligations, debts or causes of action, effective as of the Redemption Date.

Registration Rights Agreement

In connection with the July 2021 Offerings, the Company entered into a registration rights agreement, dated as of July 13, 2021 (the “Registration Rights Agreement”), with the investor named therein, pursuant to which the Company will undertake to file, within five calendar days of the date of the filing of the proxy statement seeking the Stockholder Approval, a resale registration statement to register the shares of common stock issuable upon: (i) the conversion of the Series C Preferred Stock sold in the Private Placement and (ii) the exercise of the Preferred Investment Option (the “Registrable Securities”); and to cause such registration statement to be declared effective under the Securities Act as promptly as possible after the filing thereof, but in any event no later than 75 days following the pricing date of this offering, or no later than 105 days following such date in the event of a “full review” by the SEC, and shall use its reasonable best efforts to keep such registration statement continuously effective under the Securities Act until the date that all Registrable Securities covered by such registration statement have been sold or are otherwise able to be sold pursuant to Rule 144. The Registration Rights Agreement provides for liquidated damages to the extent that the Company does not file or maintain a registration statement in accordance with the terms thereof. The Registration Rights Agreement entered into between us and the Investor on July 13, 2021, contains a triggering event which would require us to pay to any holder of the Series C Preferred Stock an amount in cash, as partial liquidated damages and not as a penalty, on a monthly basis equal to the product of 2.0% multiplied by the aggregate subscription amount paid by such holder for shares of Series C Preferred Stock pursuant to the Purchase Agreement; provided, however, that such partial liquidated damages shall not exceed 24% of the aggregate subscription amounts paid by such holders pursuant to the Purchase Agreement, or $1,977,600. If we fail to pay any partial liquidated damages within seven days after the date payable, we will be required to pay interest on any such amounts at a rate equal to the lesser of 18% per annum or the maximum rate permitted by applicable law.

During the year ended December 31, 2021, the Company did not have enough shares of authorized common stock to issue the shares of common stock issuable upon the exercise or conversion of the Series C Preferred Stock and the PIO, as applicable. For the year ended December 31, 2021, the Company attempted, but was unsuccessful, obtaining its stockholders’ approval for the increase in its shares of authorized common stock at a special meeting that was originally commenced and was subsequently adjourned on September 23, 2021, and accordingly, the Company was unable to meet its registration rights obligation as of December 31, 2021. As such, the Company recognized an aggregate of approximately $1.1 million in liquidated damages during the year ended December 31, 2021, of which includes a provision of $615,123 as an accrual for estimated damages until stockholders’ approval was achieved and the registration statement registering the shares of common stock issuable upon the exercise or conversion, as applicable, of the Series C Preferred Stock and the PIO was filed. On March 15, 2022, the Company received its stockholders’ approval to increase its authorized shares and filed a Certificate of Amendment to its Restated Certificate of Incorporation to increase the number of authorized shares from 41,666,666 shares to 63,227,273 shares on the same date. The Company filed its registration statement registering the shares of common stock issuable upon the conversion or exercise of the Series C Preferred Stock and the PIO, as applicable, on March 23, 2022 and provided for liquidated damages through that date. As of September 30, 2023, all liquidated damages had been paid and the Company no longer had any liabilities related to the Registration Rights Agreement.

3. Financing Transactions

Royalty Purchase Agreement with XOMA

On June 21, 2023, the Company, entered into (i) a Royalty Purchase Agreement (the “Royalty Agreement”) with XOMA (US) LLC (“XOMA”), for the sale, transfer, assignment and conveyance of the Company’s right, title and interest in and to certain royalty payments and milestone payments with respect to aldoxorubicin, and (ii) an Assignment and Assumption Agreement (the “Assignment Agreement”) with XOMA for the sale, transfer, assignment and conveyance of the Company’s right, title and interest in the Asset Purchase Agreement (the “2011 Arimoclomol Agreement”) between the Company and Orphazyme ApS (“Orphazyme”), dated as of May 13, 2011, and assigned to Zevra Denmark A/S (“Zevra”), effective as of June 1, 2022, which includes certain royalty and milestone payments with respect to arimoclomol. The combined aggregate purchase price paid to the Company for the sale, transfer, assignment and conveyance of the Company’s right, title and interest in and to aldoxorubicin and arimoclomol was $5 million, less certain transaction fees and expenses.

The Royalty Agreement and the Assignment Agreement also provide for up to an additional $6 million based on regulatory and commercial milestones related to the development of arimoclomol and aldoxorubicin by their respective sponsors, Zevra, Inc. and Immunity Bio, Inc. The $6 million in potential post-closing payments is comprised of $1 million upon acceptance by the Food and Drug Administration (“FDA”) of the arimoclomol New Drug Application (“NDA”), $1 million upon first commercial sale of arimoclomol, and $4 million upon FDA approval of aldoxorubicin. All royalty and milestone payments made to XOMA will be net of the existing licensing and milestone obligations owed by LadRx related to arimoclomol and aldoxorubicin.

Pursuant to the Royalty Agreement, the Company agreed to sell, transfer, assign and convey to XOMA, among other payments, all royalty payments and regulatory and commercial milestone payments payable to the Company pursuant to the worldwide license agreement, dated July 27, 2017, by and between the Company and Immunity Bio, Inc. (formerly known as NantCell, Inc.). The Royalty Agreement also provides for the sharing of certain rights with XOMA to bring any action, demand, proceeding or claim as related to receiving such payments.

Management determined that the Agreement is not considered to be with a customer, and it does not fall within the scope of ASC 606. Instead, the Agreement represents an in-substance sale of nonfinancial assets, and, therefore, should be accounted for within the scope of ASC 610-20. As such, the Company recognized such net proceeds as other income in the accompanying statement of operations.

4. Leases

We lease office space and office copiers related primarily to the administrative activities. The Company accounts for leases under ASC 842, Leases, which requires an entity to recognize a right-of-use asset and a lease liability for virtually all leases.

In January 2020, the Company signed a new four-year lease which covers approximately 2,771 square feet of office and storage space. This lease is effective March 1, 2020 and extends through February 29, 2024, with a right to extend the term for an additional five-year period, subject to the terms and conditions set forth in the lease agreement. The monthly rent is $15,361, subject to annual increases of 3.5 percent. In February 2020, the Company renewed its additional storage space lease, which requires us to make monthly payments of $1,475, subject to a 2.5 percent annual increase. The Company recorded a right of use asset and lease liability obligation of $715,310 upon inception of these leases. The Company also reclassified a previously existing right-of-use asset of $66,271 from other assets to right-of-use asset.

As of September 30, 2023, the balance of right-of-use assets was approximately $79,000, and the balance of total lease liabilities was approximately $84,000.

Future minimum lease payments under non-cancelable operating leases under ASC 842 as of September 30, 2023 are as follows:

Schedule of Future Minimum Lease Payments

		Operating Lease Payments
October 2023 – September 2024		84,181
Total future minimum lease payments		84,181
Less: present value adjustment		(651	)
Operating lease liabilities at September 30, 2023		83,530
Less: current portion of operating lease liabilities		83,530
Operating lease liabilities, net of current portion	$	—

The components of rent expense and supplemental cash flow information related to leases for the period are as follows:

Schedule of Rent Expenses and Supplement Cash Flow Information Related to Leases

	Period Ended September 30, 2023
Lease Cost
Operating lease cost (included in General and administrative expenses in the Company’s condensed Consolidated Statements of Operations)	$	150,416
Other information
Cash paid for amounts included in the measurement of lease liabilities for the period ended September 30, 2023	$	133,905
Weighted average remaining lease term – operating leases (in years)		0.4
Average discount rate		3.5	%

5. Stock Based Compensation

The Company has a 2008 Stock Incentive Plan (the “2008 Plan”) under which 50,000 shares of common stock are reserved for issuance. As of September 30, 2023, there were approximately 18,000 shares subject to outstanding stock options and approximately 8,000 shares outstanding related to restricted stock grants issued from the 2008 Plan. This plan expired on November 20, 2018 and thus no further shares are available for future grant under this plan.

In November 2019, the Company adopted the 2019 Stock Incentive Plan (the “2019 Plan”) under which 54,000 shares of common stock are reserved for issuance. As of September 30, 2023, there were 3,500 shares subject to outstanding stock options from the 2019 Plan. The 2019 Plan expires on November 14, 2029.

On September 7, 2023, the Board additionally approved and set January 16, 2024 as the grant date for certain stock options to purchase shares of common stock to certain directors and officers of the Company, which such amounts shall be determined at a future date.

There were no options granted to employees, directors or consultants in either of the periods ended September 30, 2023 or September 30, 2022.

During the nine months ended September 30, 2023, no options were exercised. During the nine months ended September 30, 2022, options to purchase 500 shares of common stock were exercised on a cashless basis in exchange for 215 shares of common stock.

Presented below is our stock option activity:

Schedule of Stock Options Activity

	Nine Months Ended September 30, 2023
	Three-Months Ended March 31, 2024
	Number of Options (Employees)			Number of Options (Non-Employees)		Total Number of Options			Weighted-Average Exercise Price
Outstanding at January 1, 2023		13,998			3,650		17,648		$	433.97
Outstanding at January 1, 2024		10,347			3,650		13,997		$	501.70
Exercised		—			—		—			—
Issued		55,000			—		55,000			1.83
Forfeited or expired		(2,001	)		—		(2,001	)	$	148.22
Exercised, forfeited or expired		—			—		—			—
Outstanding at September 30, 2023		11,997			3,650		15,647		$	745.52
Outstanding at March 31, 2024		65,647			3,650		68,997		$	103.24
Exercisable at September 30, 2023		11,997			3,650		15,647		$	745.52
Exercisable at March 31, 2024		39,391			3,650		43,041		$	164.39

The following table summarizes significant ranges of outstanding stock options under the 2008 Plan and the 2019 Plan at ~~September~~March 3031, ~~2023~~2024:

Schedule of Ranges of Outstanding Stock Options ~~under 2008 Plan and 2019 Plan~~

Range of Exercise Prices		Number of Options		Weighted-Average Remaining Contractual Life (years)		Weighted-Average Exercise Price		Number of Options Exercisable		Weighted-Average Remaining Contractual Life (years)		Weighted-Average Exercise Price
$	26. - $100.		3,500		6.21	$	26.00		3,500		6.21	$	26.00
	$1.83 - $25.99		55,000		9.80	$	1.83		29,044		9.80	$	1.83
$	101. –$300.		6,066		3.96	$	195.29		6,066		3.96	$	195.29
	$26.00 –$100.00		3,500		5.70	$	26.00		3,500		5.70	$	26.00
$	301. – $1,500.		3,500		2.08	$	1,201.28		3,500		2.08	$	1,201.28
	$100.01 – $300.00		6,066		3.46	$	195.29		6,066		3.46	$	195.29
$	1,501. –$4,146.		2,581		0.50	$	2,384.61		2,581		0.50	$	2,384.61
	$300.01 –$4,146.00		4,431		1.36	$	1,296.92		4,431		1.36	$	1,296.92
			15,647		3.47	$	745.52		15,647		3.47	$	745.52
			68,997		8.49	$	103.24		43,041		8.49	$	164.39

The Company recorded no$51,119 of stock compensation costs in ~~either~~the ~~periods~~period ended ~~September~~March 3031, ~~2023~~2024 orand ~~September~~no ~~30,~~costs ~~2022~~in asthe ~~all~~period ~~options~~ended ~~had~~March ~~previously vested.~~31, 2023. At ~~September~~March 3031, ~~2023~~2024, there was no$43,206 of unrecognized compensation expense related to unvested stock options.

14The aggregate intrinsic value of the outstanding options and options vested as of March 31, 2024 was approximately $32,000.

~~There~~At December 31, 2023, ~~was~~the noCompany ~~aggregate~~had ~~intrinsic~~warrants ~~value~~to purchase up to 42 shares of ~~the~~common stock outstanding ~~options~~at ~~and~~a ~~options~~weighted ~~vested~~average asexercise price of ~~September~~$1,044.00 per 30share, ~~2023~~which expired in 2024, and as such, the Company had no outstanding warrants at March 31, 2024.

~~As of September 30, 2023 and September 30, 2022, the Company had warrants to purchase up to 42 shares of common stock outstanding at a weighted average exercise price of $1,044~~4.~~00 per share. As of September 30, 2023, warrants to purchase up to 42 shares of common stock outstanding~~ ~~had no intrinsic value.~~Xoma

6.Royalty ~~Stockholder~~Purchase ~~Protection~~Agreement ~~Rights~~with ~~Plan~~XOMA

On ~~December~~June 1321, ~~2019~~2023, the ~~Board~~Company, ~~authorized~~entered ~~and~~into ~~declared~~(i) a ~~dividend~~Royalty ofPurchase ~~one~~Agreement ~~right~~ (athe “~~Right~~Royalty Agreement”) with XOMA (US) LLC (“XOMA”), for ~~each~~the sale, transfer, assignment and conveyance of the Company’s ~~issued~~ right, title and ~~outstanding~~interest ~~shares~~in ofand ~~common~~to ~~stock,~~certain ~~par~~royalty ~~value~~payments and ~~$0.001~~milestone ~~per~~payments ~~share.~~with ~~The~~respect ~~dividend~~to ~~was~~aldoxorubicin, ~~paid~~and to(ii) ~~the~~an ~~stockholders~~Assignment ofand ~~record~~Assumption atAgreement (the “Assignment Agreement”) ~~close~~with ofXOMA ~~business~~for onthe ~~December~~sale, 23transfer, ~~2019.~~assignment ~~Each~~and ~~Right~~conveyance ~~entitled~~of the ~~registered~~Company’s ~~holder~~right, ~~subject~~title toand ~~the~~interest ~~terms~~in of the ~~Original~~Asset ~~Rights~~Purchase Agreement (asthe ~~defined~~“2011 ~~below~~Arimoclomol Agreement”), tobetween ~~purchase from~~ the Company ~~one~~and ~~one-thousandth~~Orphazyme ofApS a(“Orphazyme”), ~~share~~dated as of ~~the~~May ~~Company’s~~13, ~~Series B Junior Participating Preferred Stock~~2011, and ~~par~~assigned ~~value~~to ~~$0.01~~Zevra ~~per~~Denmark ~~share~~A/S (~~the~~ “~~Series~~Zevra ~~B Preferred Stock~~Denmark”), ateffective aas ~~price~~ of ~~$5.00~~June ~~(the~~1, ~~“Purchase Price”)~~2022, ~~subject~~ towhich includes certain ~~adjustments~~royalty and milestone payments with respect to arimoclomol. The ~~description~~combined ~~and~~aggregate ~~terms~~purchase ofprice ~~the~~paid ~~Rights~~to ~~were~~the ~~set~~Company ~~forth~~for in the ~~Rights~~sale, ~~Agreement~~transfer, ~~dated~~assignment asand conveyance of ~~December 13, 2019 (~~the ~~“Original~~Company’s ~~Rights Agreement”)~~right, bytitle and ~~between~~interest ~~the~~in ~~Company~~ and ~~American~~to ~~Stock~~aldoxorubicin ~~Transfer~~and &arimoclomol ~~Trust~~was ~~Company,~~$5 ~~LLC~~million, less certain transaction asfees ~~Rights~~and ~~Agent~~expenses.

On November 12, 2020, the Board approved an amendment and restatement of the Original Rights Agreement (as amended and restated, the “Amended and Restated Rights Agreement”) to effect certain changes to the Original Rights Agreement, including (i) reducing the duration to a term of three years, subject to certain earlier expiration as described in more detail below, and (ii) lowering the beneficial ownership threshold at which a person or group of persons becomes an Acquiring Person (as defined below) to 4.95% or more of the Company’s outstanding shares of common stock, subject to certain exceptions. The Amended and Restated Rights Agreement is designed to discourage (i) any person or group of persons from acquiring beneficial ownership of more than 4.95% of the Company’s shares of common stock and (ii) any existing stockholder currently beneficially holding 4.95% or more of the Company’s shares of common stock from acquiring additional shares of the Company’s common stock.11

The ~~purpose~~Royalty ofAgreement and the ~~Amended~~Assignment ~~and~~Agreement ~~Restated~~also ~~Rights~~provides ~~Agreement~~for isup to ~~protect~~an ~~value~~additional by$6 ~~preserving~~million ~~the~~based ~~Company’s~~on ~~ability~~regulatory toand ~~utilize~~commercial ~~its net~~milestones ~~operating~~related ~~losses~~to ~~and~~the ~~certain~~development ~~other~~of ~~tax~~arimoclomol ~~attributes~~and ~~(collectively,~~aldoxorubicin ~~the~~by ~~“Tax~~their ~~Benefits”)~~respective tosponsors, ~~offset~~Zevra, ~~potential~~Inc. ~~future~~and ~~income~~Immunity ~~tax obligations~~Bio. The ~~Company’s~~$6 ~~ability to use its Tax Benefits would be substantially limited if it experiences an “ownership~~million ~~change,”~~in aspotential ~~such~~post-closing ~~term~~payments is ~~defined~~comprised ~~in Section 382~~ of ~~the~~$1 ~~Internal~~million ~~Revenue~~upon ~~Code~~acceptance ofby ~~1986, as amended (~~the ~~“Tax~~FDA ~~Code”). A corporation generally will experience an ownership change if the percentage~~ of the ~~corporation’s~~arimoclomol ~~stock~~New ~~owned~~Drug byApplication ~~its~~ (“~~5-percent shareholders,~~NDA”), $1 asmillion ~~defined~~upon infirst ~~Section~~commercial ~~382~~sale of ~~the Tax Code~~arimoclomol, ~~increases~~and by$4 ~~more~~million ~~than~~upon 50FDA ~~percentage~~approval ~~points~~of ~~over their lowest ownership percentage within a rolling three-year period~~aldoxorubicin. ~~The~~All ~~Amended~~royalty and ~~Restated~~milestone ~~Rights~~payments made ~~Agreement~~to isXOMA ~~intended~~will tobe ~~reduce~~net ~~the~~of ~~likelihood~~ the ~~Company would~~existing ~~experience~~licensing anand ~~ownership~~milestone ~~change~~obligations ~~under~~owed ~~Section~~by ~~382~~LadRx ofrelated ~~the~~to ~~Tax~~arimoclomol ~~Code~~and aldoxorubicin.

~~The~~Pursuant ~~Rights will not be exercisable until the earlier~~ to ~~occur of (i)~~ the ~~close~~Royalty ofAgreement, ~~business on~~ the ~~tenth~~Company ~~business~~agreed ~~day~~to ~~after~~sell, atransfer, ~~public~~assign ~~announcement or~~and ~~filing~~convey ~~that~~to aXOMA, ~~person~~among orother ~~group of affiliated or associated persons has become an “Acquiring Person~~payments,” ~~which~~all isroyalty ~~defined as~~payments aand ~~person~~regulatory ~~or group of affiliated or associated persons that, at any time after the date of the Amended~~ and ~~Restated~~commercial ~~Rights~~milestone ~~Agreement, has~~payments ~~acquired,~~payable ~~or obtained the right~~ to ~~acquire, beneficial ownership of 4.95% or more of~~ the Company’s ~~outstanding~~pursuant ~~shares of common stock, subject~~ to ~~certain exceptions or (ii)~~ the ~~close~~worldwide oflicense ~~business~~agreement, ondated ~~the~~July ~~tenth business day after the commencement of~~27, ~~or announcement~~2017, ofby anand ~~intention~~between ~~to commence, a tender offer or exchange offer~~ the ~~consummation~~Company ofand ~~which~~Immunity ~~would~~Bio, ~~result~~Inc.. inThe ~~any~~Royalty ~~person~~Agreement ~~becoming~~also anprovides ~~Acquiring Person~~for (the ~~earlier~~sharing of ~~such~~certain ~~dates~~rights ~~being~~with ~~called~~XOMA ~~the~~to bring ~~“Distribution~~any ~~Date”) (provided~~action, ~~however~~demand, ~~that~~proceeding ~~if such tender~~ or ~~exchange~~claim ~~offer~~as isrelated ~~terminated prior~~ to ~~the~~receiving ~~occurrence of the Distribution Date, then no Distribution Date shall occur as a result of~~ such ~~tender or exchange offer)~~payments.

~~The~~Management ~~Rights,~~determined ~~which~~that ~~are not exercisable until~~ the ~~Distribution~~Royalty ~~Date,~~Agreement ~~will~~is ~~expire~~not atconsidered ~~or prior~~ to ~~the~~be ~~earliest~~with ofa ~~(i) the close of business on November 16~~customer, ~~2023;~~and ~~(ii)~~it ~~the~~does ~~time~~not atfall ~~which~~within the ~~Rights~~scope ~~are~~of ~~redeemed~~ASC ~~pursuant~~606. ~~to the Amended and Restated Rights Agreement; (iii) the time~~Instead, ~~at which~~ the ~~Rights~~Royalty ~~are exchanged pursuant to the Amended and Restated Rights~~ Agreement; ~~(iv)~~represents ~~the~~an ~~time at which the Rights are terminated upon the occurrence of certain mergers or other transactions approved~~ in-substance ~~advance~~sale ~~by the Board; and (v) the close~~ of ~~business~~nonfinancial onassets, ~~the date set by the Board following a determination by the Board that (x) the Amended~~ and, ~~Restated~~therefore, ~~Rights~~should ~~Agreement~~be isaccounted ~~no longer necessary or desirable~~ for ~~the~~within ~~preservation of~~ the ~~Tax Benefits or (y) no Tax Benefits are available to be carried forward or are otherwise available~~scope ~~(the earliest~~ of ~~(i),~~ASC ~~(ii), (iii), (iv) and (v) is referred to as the “Expiration Date”)~~610-20.

~~Each~~Assignment ~~share of Series B Preferred Stock will be entitled, when, as~~ and ifAssumption ~~declared,~~Agreement towith a preferential per share quarterly dividend payment equal to the greater of (i) $1.00 per share or (ii) an amount equal to 1,000 times the dividend declared per share of common stock. Each share of Series B Preferred Stock will entitle the holder thereof to 1,000 votes on all matters submitted to a vote of the stockholders of the Company. In the event of any merger, consolidation or other transaction in which shares of common stock are converted or exchanged, each share of Series B Preferred Stock will be entitled to receive 1,000 times the amount received per one share of common stock.XOMA

15On June 21, 2023, the Company entered into the Assignment Agreement with XOMA, pursuant to which, among others, the Company agreed to sell, transfer and assign to XOMA the Company’s right, title and interest in the arimoclomol pursuant to the 2011 Arimoclomol Agreement, including the right to receive certain milestone, royalty and other payments from Zevra Denmark.

~~The~~Pursuant ~~Purchase~~to ~~Price payable, and~~ the ~~number~~Assignment ~~of shares of Series B Preferred Stock or other securities or property issuable~~Agreement, ~~upon exercise of~~ the ~~Rights~~Company ~~are~~is ~~each~~entitled ~~subject~~ to ~~adjustment~~receive ~~from time to time to prevent dilution~~ (i) ina ~~the~~one-time ~~event~~payment of a$1 ~~stock~~million ~~dividend~~upon ~~on,~~acceptance orof a ~~subdivision,~~re-submission ~~combination~~of oran ~~reclassification~~NDA ofto the ~~Series~~FDA Bfor ~~Preferred Stock~~arimoclomol, and (ii) ~~upon~~a ~~the~~one-time ~~grant~~payment toof ~~holders~~$1 ofmillion upon the ~~Series~~first Binvoiced ~~Preferred~~sale ~~Stock~~in of certain ~~rights~~ orterritories ~~warrants to subscribe for or purchase Series B Preferred Stock or convertible securities at less than the then-current market~~of ~~price~~a ofpharmaceutical ~~the~~product ~~Series~~derived Bfrom ~~Preferred~~arimoclomol ~~Stock~~as oran ~~(iii)~~active ~~upon~~pharmaceutical ~~the~~ingredient, ~~distribution~~subject to ~~holders of~~ the ~~Series~~receipt ~~B Preferred Stock~~ of ~~evidences~~the ofapplicable ~~indebtedness~~regulatory orapproval ~~assets~~required ~~(excluding~~to ~~regular~~sell ~~periodic~~such ~~cash~~a ~~dividends~~product ~~or dividends payable~~ in ~~Series~~such Bcountries. ~~Preferred~~In ~~Stock)~~January or2024, ofZevra ~~subscription~~announced ~~rights~~the orFDA ~~warrants (other~~had ~~than~~accepted ~~those~~the ~~referred~~NDA tofor ~~above). The number of outstanding Rights~~ arimoclomol and the ~~number~~Company ofreceived ~~one~~the one-~~thousandths~~time payment of a$1 ~~share~~million ofin ~~Series~~February B2024 ~~Preferred Stock~~recognized ~~issuable~~such ~~upon~~net ~~exercise~~proceeds of ~~each~~$1.0 ~~Right~~million ~~are~~as ~~also~~other ~~subject to adjustment~~ income in the ~~event~~statement of aoperations ~~stock~~for ~~split,~~the ~~reverse~~period ~~stock~~ended ~~split~~March 31, ~~stock~~2024 ~~dividends and other similar transactions involving the common stock.~~

In5. ~~the~~Commitments ~~event that any person or group of affiliated or associated persons becomes an Acquiring Person, each holder of a Right, other than the Rights beneficially owned by the Acquiring Person, affiliates~~ and associates of the Acquiring Person and certain transferees thereof (which will thereupon become null and void), will thereafter have the right to receive upon exercise of a Right that number of shares of common stock having a market value of two times the Purchase Price.Contingencies

In the event that, after a person or a group of affiliated or associated persons has become an Acquiring Person, the Company is acquired in a merger or other business combination transaction, or 50% or more of the Company’s assets or earning power are sold, proper provision will be made so that each holder of a Right will thereafter have the right to receive, upon the exercise thereof at the then-current purchase price of the Right, that number of shares of common stock of the acquiring company having a market value at the time of that transaction equal to two times the Purchase Price.

With certain exceptions, no adjustment in the Purchase Price will be required unless such adjustment would require an increase or decrease of at least one percent (1%) in the Purchase Price. No fractional shares of Series B Preferred Stock will be issued (other than fractions which are integral multiples of one one-thousandth of a share of Series B Preferred Stock, which may, at the election of the Company, be evidenced by depositary receipts) and, in lieu thereof, an adjustment in cash will be made based on the market price of the Series B Preferred Stock on the trading day immediately prior to the date of exercise.

At any time after any person or group of affiliated or associated persons becomes an Acquiring Person and prior to the acquisition of beneficial ownership by such Acquiring Person of 50% or more of the outstanding shares of common stock, the Board, at its option, may exchange each Right (other than Rights owned by such person or group of affiliated or associated persons which will have become void), in whole or in part, at an exchange ratio of one share of common stock per outstanding Right (subject to adjustment).

In connection with any exercise or exchange of the Rights, no holder of a Right will be entitled to receive shares of common stock if receipt of such shares would result in such holder, together with such holder’s affiliates and associates, beneficially owning more than 4.95% of the then-outstanding common stock (such shares, the “Excess Shares”) and the Board determines that such holder’s receipt of Excess Shares would jeopardize or endanger the value or availability of the Tax Benefits or the Board otherwise determines that such holder’s receipt of Excess Shares is not in the best interests of the Company. In lieu of such Excess Shares, such holder will only be entitled to receive cash or a note or other evidence of indebtedness with a principal amount equal to the then-current market price of the common stock multiplied by the number of Excess Shares that would otherwise have been issuable.

At any time before the Distribution Date, the Board may redeem the Rights in whole, but not in part, at a price of $0.001 per Right (subject to certain adjustments) (the “Redemption Price”). The redemption of the Rights may be made effective at such time, on such basis and with such conditions as the Board in its sole discretion may establish.

Immediately upon the action of the Board electing to redeem or exchange the Rights, the Company shall make a public announcement thereof, and upon such election, the right to exercise the Rights will terminate and the only right of the holders of Rights will be to receive the Redemption Price.

Until a Right is exercised or exchanged, the holder thereof, as such, will have no rights as a stockholder of the Company, including, without limitation, the right to vote or to receive dividends.

The Board may amend or supplement the Amended and Restated Rights Agreement without the approval of any holders of Rights, including, without limitation, in order to (a) cure any ambiguity, (b) correct inconsistent provisions, (c) alter time period provisions, including the Expiration Date, or (d) make additional changes to the Amended and Restated Rights Agreement that the Board deems necessary or desirable. However, from and after the date any person or group of affiliated or associated persons becomes an Acquiring Person, the Amended and Restated Rights Agreement may not be supplemented or amended in any manner that would adversely affect the interests of the holders of Rights.

7. Commitments and Contingencies

Commitments

Aldoxorubicin

WeThe ~~have~~Company has an agreement (the “Vergell Agreement”) with Vergell Medical (formerly with KTB Tumorforschungs GmbH) (“Vergell”) for the exclusive license of patent rights held by Vergell for the worldwide development and commercialization of aldoxorubicin. Under the agreement, we had to make payments to Vergell upon meeting certain clinical and regulatory milestones up to and including the product’s second final marketing approval. However, those payments are no longer required since the intellectual property acquired under the Vergell Agreement expired. We accrued $316,000 that we believe was owed prior to the expiry of the intellectual property. This amount was outstanding at ~~September~~March 3031, ~~2023~~2024 and December 31, ~~2022~~2023.

Arimoclomol

The agreement relating to our worldwide rights to arimoclomol provides for our payment of up to an aggregate of $3.65 million upon receipt of milestone payments from Orphayzme A/S. On May 31, 2022, Orphazyme announced that it had completed the sale of substantially all of its assets and business activities for cash consideration of $12.8 million and assumption of liabilities estimated to equal approximately $5.2 million to KemPharm (the “KemPharm Transaction”). KemPharm is a specialty biopharmaceutical company focused on the discovery and development of novel treatments for rare central nervous system (“CNS”) diseases. As part of the KemPharm Transaction, all of Orphazyme’s obligations to LadRx under the 2011 Arimoclomol Agreement, including with regard to milestone payments and royalties on sales, were assumed by KemPharm. KemPharm re-branded to Zevra Therapeutics, Inc. in February 2023.

As disclosed in Note 3, Assignment Agreement with XOMA, pursuant to the Assignment Agreement, although all the liabilities and obligations related to arimoclomol remain the responsibility of the Company, XOMA will direct an escrow agent appointed by them to pay on behalf of LadRx up to an aggregate of $3.25 million reflected in the preceding paragraph, as well as all future obligations related to Steven A. Kriegsman, pursuant to the Amended and Restated Employment Agreement, as amended by and between the Company and Mr. Kriegsman, dated March 26, 2019.12

As discussed in Note 6, pursuant to the Assignment Agreement, although all the liabilities and obligations related to arimoclomol remain the responsibility of the Company, XOMA will direct an escrow agent appointed by them to pay on behalf of LadRx up to an aggregate of $3.25 million reflected in the preceding paragraph, as well as all future obligations related to Steven A. Kriegsman, pursuant to the Amended and Restated Employment Agreement, as amended by and between the Company and Mr. Kriegsman, dated March 26, 2019.

Innovive

Under the merger agreement by which wethe Company acquired Innovive Pharmaceuticals, Inc. (“Innovive”), we agreed to pay the former Innovive stockholders a total of up to approximately $18.3 million of future earnout merger consideration, subject to our achievement of specified net sales under the Innovive license agreements. As of ~~September~~March 3031, ~~2023~~2024, there are no longer any further obligations due under this agreement, since the licensed intellectual property rights have expired.

Contingencies

We apply the disclosure provisions of ASC 460, Guarantees (“ASC 460”) to its agreements that contain guarantees or indemnities by the Company. We provide (i) indemnifications of varying scope and size to certain investors and other parties for certain losses suffered or incurred by the indemnified party in connection with various types of third-party claims; and (ii) indemnifications of varying scope and size to officers and directors against third party claims arising from the services they provide to the Company.

The Company is occasionally involved in legal proceedings and other matters arising from the normal course of business. On November 30, 2022, Jerald Hammann (“Hammann”) filed a complaint (the “Complaint”) against the Company, Mr. Caloz, and Mr. Kriegsman (together, “Defendants”) in the Court of Chancery of the State of Delaware, alleging various violations of a Cooperation Agreement, dated August 21, 2020, by and between the Company and Hammann. The Complaint alleges breaches of a provision limiting the Board’s ability to effect discretionary compensation and a non-disparagement provision. The Complaint further alleges a breach of a purported implied obligation that the Company disclose various internal records to Hammann. Defendants ~~have~~ moved to dismiss the Complaint in its entirety. ~~Hammann~~As ~~has~~a ~~opposed~~result, the ~~motion~~Court tosubsequently ~~dismiss~~dismissed the claims against Mr. Caloz and ~~briefing~~Mr. Kriegsman and also dismissed one of the ~~motion~~claims isagainst ~~ongoing~~the Company. ~~Defendants~~The ~~intend~~Company intends to litigate vigorously against Hammann’s claims. ~~A hearing is scheduled for December 2023.~~

~~The Company~~We ~~evaluates~~have ~~developments in legal proceedings~~ directors’ and ~~other~~officers’ ~~matters~~liability oninsurance, awhich ~~quarterly~~will ~~basis.~~be ~~The~~utilized, ~~Company~~after ~~records accruals for loss contingencies to~~ the ~~extent~~deductible, ~~that~~in the ~~Company~~defense ~~concludes that it is probable that a liability has been incurred and the amount~~ of ~~the~~any ~~related~~matter ~~loss~~involving ~~can~~our directors beor ~~reasonably estimated~~officers.

17The Company evaluates developments in legal proceedings and other matters on a quarterly basis. If an unfavorable outcome becomes probable and reasonably estimable, we could incur charges that could have a material adverse impact on our financial condition and results of operations for the period in which the outcome becomes probable and reasonably estimable.

Item 2. — Management’s Discussion and Analysis of Financial Condition and Results of Operations

Overview

LadRx Corporation (“LadRx” the “Company”, “we”, “us”, or “our”) is a biopharmaceutical research and development company specializing in oncology. The Company’s focus is on the discovery, research and clinical development of novel anti-cancer drug candidates that employ novel technologies that target chemotherapeutic drugs to solid tumors and reduce off-target toxicities. During 2017, ~~LadRx~~the Company’s discovery laboratory in Freiburg, Germany, synthesized and tested over 75 rationally designed drug ~~conjugates~~candidates with highly potent anti-cancer payloads, culminating in the creation of two distinct classes of compounds. Four lead candidates (LADR-7 through LADR-10) were selected based on in vitro and animal studies in several different cancer models, and based on stability, and manufacturing feasibility. In addition, a novel companion diagnostic, ACDx™, was developed to identify patients with cancer who are most likely to benefit from treatment with these drug candidates.

On June 1, 2018, ~~LadRx~~the Company launched Centurion BioPharma Corporation (“Centurion”), a wholly-owned subsidiary, and transferred into Centurion all of its assets, liabilities and personnel associated with the laboratory operations in Freiburg, Germany. In ~~connection~~ connection with said transfer, the Company and Centurion entered into a Management Services Agreement whereby the Company agreed to render advisory, consulting, financial and administrative services to Centurion, for which Centurion shall reimburse the Company for the cost of such services plus a 5% service charge. On December 21, 2018, LadRx announced that Centurion had concluded the pre-clinical phase of development for its four LADR™ (Linker Activated Drug Release) drug candidates, and offor its ~~albumin~~ companion diagnostic (ACDx™). As a result of completing this work, operations taking place at the pre-clinical laboratory in Freiburg, Germany were no longer needed and the lab was closed at the end of January 2019.

On March 9, 2022, Centurion merged with and into LadRx, with LadRx absorbing all of Centurion’s assets and continuing after the merger as the surviving entity (the “Merger”). The Merger was implemented through an agreement and plan of merger pursuant to Section 253 of the General Corporation Law of the State of Delaware and did not require approval from either our or Centurion’s stockholders. The Certificate of Ownership merging Centurion into LadRx was filed with the Secretary of State of Delaware on March 9, 2022.

Effective September 26, 2022, we changed our name from CytRx Corporation to LadRx Corporation pursuant to a Certificate of Amendment to our Certificate of Incorporation filed with the Secretary of State of Delaware. In accordance with the General Corporation Law of the State of Delaware (the “DGCL”), our board of directors approved the name change and the Certificate of Amendment. Pursuant to Section 242(b)(1) of the DGCL, stockholder approval was not required for the name change or the Certificate of Amendment.

~~Reverse~~2023 Reverse Stock Split

The Company effected a 1-for-100 reverse stock split (the “Reverse Stock Split”) of its issued and outstanding shares of common stock on May 17, 2023, pursuant to which every 100 shares of the Company’s issued and outstanding shares of common stock were converted into one share of common stock without any change in the par value per share. Any fraction of a share of common stock that would otherwise have resulted from the Reverse Stock Split ~~were~~was rounded up to the nearest whole share. All share and per share amounts in this Quarterly Report on Form 10-Q (~~the~~this “Quarterly Report”) have been adjusted to reflect the ~~reverse~~Reverse ~~stock split~~Stock Split as if it had occurred at the beginning of the earliest period presented.

Corporate Information

We are a Delaware corporation, incorporated in 1985. Our corporate offices are located at 11726 San Vicente Boulevard, Suite 650, Los Angeles, California 90049, and our telephone number is (310) 826-5648. Our web site is located at ~~http://~~www.ladrxcorp.com. We do not incorporate by by reference into this Quarterly Report the information on, or accessible through, our website, and you should not consider it as part of this report.

LADR Drug Discovery Platform

~~The~~ LADR™-based ~~Technology~~drugs ~~offers~~are targeted therapeutics that offer the ~~opportunity~~benefit ~~for~~of ~~multiple~~targeting, ~~pipeline~~without ~~drugs~~some of the drawbacks that come with large molecules, such as antibodies. The Company’s LADR™ technology platform consists of an organic backbone that is attached to a chemotoxic agent. The purpose of the LADR™ backbone is to first target and deliver the chemotoxic agent to the tumor environment, and then to release the chemotoxic agent within the tumor. By delivering, concentrating, and releasing the chemotoxic agent within the tumor, one expects to reduce the off-target side-effects of the chemotherapeutic, which in turn allows for several-fold higher dosing of the chemotherapeutic to the patient. Being small organic molecules, the Company expects LADR-based drugs to offer the benefits of targeting the tumor without the complexity, side effects, and expense inherent in macromolecules ~~such~~ such as antibodies and nanoparticles.

The Company’s LADR-based drugs use circulating albumin as the binding target and as the trojan horse to deliver the LADR™ ~~drugs~~ drugs to the tumor., thus LADR-based drugs are not limited in their use to targets that are specific to the cancer being treated. Albumin is the most abundant protein in ~~plasma~~human and accumulates inside tumors due to the aberrant vascular structure ~~that~~and draining system that exists within solid tumors. Tumors use albumin as a nutritional source and for transport of signaling and other molecules that are important to the maintenance and growth of the tumor, which makes albumin an excellent target for drugs that are intended for solid tumors.

The Company’s LADR™ development efforts are focused on two classes of ultra-high potency albumin-binding drugs. These LADR-based drugs, LADRs 7, 8, 9, and 10, combine the proprietary LADR™ backbone with novel derivatives of the auristatin and maytansinoid drug classes. Auristatin and maytansinoid are highly potent chemotoxins, and require targeting to the tumor for safe administration to humans, as is the case for the U.S. Food and Drug Administration (“FDA”)-approved drugs Adcetris (auristatin antibody-drug-conjugate manufactured by Seagen, Inc.) and Kadcyla (maytansine antibody-drug-conjugate manufactured by Genentech, Inc.). We believe that LADR-based drugs offer the benefits of tumor targeting without the disadvantages of antibodies and other macromolecules, which include expense, complexity, and negative side effects. Additionally, albumin is a very well-characterized drug target, which we believe will reduce clinical and regulatory costs and risks.14

The first LADR-based drug is aldoxorubicin. Aldoxorubicin consists of the widely used chemotoxin doxorubicin attached to a LADR backbone that targets the drug to the tumor, and releases the active drug once inside the tumor. Aldoxorubicin has been administered to hundreds of patients in clinical trials in soft tissue sarcoma and glioblastoma. As expected for a LADR-based drug, aldoxorubicin is typically dosed at a level that provides 3-4 times the amount of doxorubicin that can be safely delivered to a patient. In a large Phase II study in advanced soft tissue sarcomas, aldoxorubicin met its primary endpoint in extending progression-free survival (PFS). The drug also proved the value of LADR targeting in that it showed far less cardiotoxicity, one of the major issues with the use of doxorubicin. This advantage in cardiotoxicity offered by aldoxorubicin over doxorubicin was also shown in a subsequent Phase III trial in soft tissue sarcoma. The primary PFS endpoint was not met in this Phase III trial, in which 2/3 of the patients in the aldoxorubicin group were known to have already progressed after treatment with doxorubicin, making efficacy results difficult to interpret in this Phase III trial, but the cardiac safety of aldoxorubicin versus doxorubicin was demonstrated in a subgroup of leiomyosarcoma and liposarcoma patients. Preliminary clinical data has also been obtained in glioblastoma, Kaposi Sarcoma, and small cell lung cancer. Aldoxorubicin is currently licensed to Immunity Bio (see below).

The Company’s efforts at furthering LADR™ development are focused on two classes of ultra-high potency albumin-binding drugs. These LADR-based drugs, LADR7, 8, 9, and 10, combine the proprietary LADR™ backbone with novel derivatives of the auristatin and maytansinoid drug classes. Auristatin and maytansinoid are highly potent chemotoxins, and require targeting to the tumor for safe administration to humans, as is the case for the U.S. Food and Drug Administration (“FDA”)-approved drugs Adcetris (auristatin antibody-drug-conjugate manufactured by Seagen, Inc.) and Kadcyla (maytansine antibody-drug-conjugate manufactured by Genentech, Inc.). We believe that LADR-based drugs offer the benefits of tumor targeting without the disadvantages of antibodies and other macromolecules, which include expense, complexity, and negative side effects. Additionally, albumin is a very well-characterized drug target, which we believe will reduce clinical and regulatory costs and risks.

The Company’s postulated mechanism of action for LADR-based drugs is as follows:

● after administration, the linker portion of the drug conjugate forms a rapid and specific covalent bond to the cysteine-34 position of circulating albumin; ● circulating albumin preferentially accumulates in tumors due to a mechanism called “enhanced permeability and retention”, which results in lower exposure to the drug in noncancerous tissues of the heart, liver, and other organs; ● once localized at the tumor, the acid-sensitive linker of the LADR™ backbone is cleaved due to the specific conditions within the tumor and in the tumor microenvironment; and ● free active drug is then released within the tumor, causing tumor cell death.

~~The first-generation~~● ~~LADR-based~~circulating ~~drug~~albumin ispreferentially ~~called~~accumulates ~~Aldoxorubicin.~~in ~~Aldoxorubicin~~tumors isdue ~~the well-known drug doxorubicin attached~~ to ~~the first generation LADR™ backbone (LADRs 7-10 employ~~ a ~~next~~mechanism ~~generation~~called ~~LADR™~~“Enhanced ~~backbone).~~Permeability ~~Aldoxorubicin~~and ~~has~~Retention”, ~~been~~which ~~administered~~results ~~to over 600 human subjects~~ in ~~human~~lower ~~clinical~~exposure ~~trials~~to ~~and has proven~~ the ~~concept~~drug ~~of LADR™~~ in ~~that~~noncancerous ~~several-fold~~tissues ~~more~~of ~~doxorubicin can be safely administered to patients when~~ the ~~doxorubicin~~heart, isliver, ~~attached to LADR™ than when administered as native doxorubicin. Aldoxorubicin has been licensed to ImmunityBio~~ and isother ~~currently in a Phase II trial for pancreatic cancer.~~organs;

~~The next~~● ~~generation~~once ~~LADR™~~localized ~~drugs~~at ~~are~~the ~~termed LADR 7~~tumor, 8,the 9,acid-sensitive ~~and~~linker ~~10. A great deal~~ of ~~Investigational~~the ~~New Drug (“IND”) enabling work has already been accomplished on~~ LADR™ ~~7-10,~~backbone ~~including~~is ~~in-silico~~cleaved ~~modeling,~~due ~~in-vitro~~to ~~efficacy~~the ~~testing~~specific inconditions ~~several~~within ~~different~~the ~~cancer~~tumor ~~models, in-vivo dosing, safety,~~ and ~~efficacy testing~~ in ~~several~~the ~~different~~tumor ~~cancer~~microenvironment; ~~models in animals. We have also developed~~ and ~~proven manufacturability, an important step prior to beginning human clinical trials.~~

19● free active drug is then released within the tumor, causing tumor cell death.

The ~~IND~~first-~~enabling~~generation ~~work~~LADR-based ~~that~~drug ~~remains~~is ~~prior~~called toAldoxorubicin. ~~applying~~Aldoxorubicin tois the ~~FDA~~doxorubicin ~~for~~attached ~~first-in-human~~to ~~studies~~the ~~for~~first generation LADR™ backbone (LADRs 7-10 isemploy ~~limited~~a ~~due~~next togeneration ~~the~~LADR™ ~~extensive experimentation already completed~~backbone). ~~For~~Aldoxorubicin ~~example,~~has inbeen ~~the~~administered ~~case~~to ofover ~~LADR~~600 7,human asubjects ~~manufacturing~~in human ~~run~~clinical ~~under~~trials ~~Good~~and ~~Manufacturing~~has ~~Practices~~proven ~~(GMP)~~the ~~must~~concept beof ~~completed and~~LADR™ ~~some~~in ~~toxicology~~that ~~studies~~several-fold ~~completed~~more ~~using~~doxorubicin ~~the~~can ~~GMP~~be ~~material~~safely ~~must~~administered beto ~~completed~~patients when inthe ~~animals.~~doxorubicin ~~Toxicology~~is ~~studies~~attached ~~with~~to LADR™ 7than ~~have~~when ~~already been~~administered ~~completed~~as ~~with~~native ~~non-GMP~~doxorubicin. ~~manufactured~~Aldoxorubicin ~~drug~~has been licensed to ImmunityBio.

~~Over the past quarter, LadRx~~The ~~and~~next ~~its~~generation ~~Contract~~LADR™ ~~Drug~~drugs ~~Manufacturing~~are ~~Organization~~termed ~~(CDMO)~~LADR7, ~~have~~8, ~~been~~9, ~~working~~and ~~towards~~10. ~~the~~A ~~GMP~~great ~~manufacture~~deal of ~~LADR7.~~Investigational ~~Thus~~New ~~far,~~Drug ~~the~~(“IND”) ~~synthetic~~enabling ~~steps~~work tohas ~~construct~~already ~~LADR7~~been ~~have~~accomplished ~~been~~on ~~carried~~LADR7-10, ~~out~~including ~~and~~in-silico ~~validated~~modeling, ~~most~~in-vitro ofefficacy ~~the~~testing ~~synthetic~~in ~~steps~~several ~~have~~different ~~been~~cancer ~~optimized~~models, in-vivo ~~for~~dosing, ~~scaleup~~safety, and ~~LADR7~~efficacy ~~drug product~~testing ~~has been produced~~ in ~~sufficient~~several ~~quantities~~different tocancer ~~begin~~models ~~IND-enabling~~in ~~toxicology experiments~~animals. AsWe ~~the~~have ~~toxicology~~also ~~program~~developed ~~starts~~and inproven ~~the~~manufacturability, ~~fourth~~an ~~quarter~~important ofstep ~~2023,~~prior ~~work~~to onbeginning ~~the~~human ~~manufacturing side will continue, with a goal of scaling up the manufacturing of LADR7 to~~ clinical ~~quantities~~ trials.

~~LadRx~~The IND-enabling ~~plans~~work that remains prior to ~~submit~~applying to the FDA afor ~~pre~~first-~~IND (pre~~in-~~Investigational~~human ~~New~~studies ~~Drug)~~for ~~meeting~~LADR ~~request~~7-10 ~~during~~is ~~the~~limited ~~fourth~~due ~~quarter of~~to ~~2023~~the ~~for~~extensive experimentation ~~LADR7,~~already ~~and~~completed. ~~projects~~For aexample, ~~full~~in ~~IND submission with~~ the ~~FDA~~case inof ~~the~~LADR ~~second~~7, ~~quarter~~a ofmanufacturing ~~2023.~~run ~~The~~under ~~Company~~Good ~~hopes~~Manufacturing toPractices ~~obtain~~(GMP) ~~IND clearance~~has ~~for~~been ~~LADR7~~completed ~~during~~and ~~calendar~~the ~~year~~GMP ~~2024~~LADR or7 ~~early~~currently ~~2025.~~in ~~Furtherance~~hand ofis ~~LADR7~~sufficient to ~~IND~~carry ~~clearance~~out byfinal ~~the~~toxicology ~~FDA requires additional funding~~studies, and ~~could be~~to ~~impacted~~initiate byPhase ~~timing~~IA orstudies in ~~technical~~human ~~delays~~subjects.

~~Management~~The final ~~estimates~~toxicology ~~that~~studies ~~these~~required ~~final~~for the IND~~-enabling~~ ~~activities~~ for LADR 7 ~~would~~are ~~take~~underway ~~approximately 12~~and ~~months~~we toexpect ~~complete,~~the ~~once~~toxicology ~~funded~~studies ~~and~~to ~~initiated,~~be completed and ~~that~~the ~~first-in-human~~IND application ~~dosing~~for ~~would~~LADR 7 to be ~~achieved~~filed ~~within~~with ~~approximately~~the ~~6-9~~FDA ~~months~~by ~~after completion~~the end of the ~~IND-enabling~~third ~~studies.~~quarter ~~Management~~of ~~further~~2024 ~~estimates~~or ~~that~~the beginning of the ~~cost~~fourth toquarter ~~manufacture~~of ~~GMP~~2024. Absent ~~material~~a ~~for~~clinical ~~one~~hold ~~LADR™~~from ~~drug~~the FDA, this timeline should allow the Company to be ready for ~~example~~first-patient dosing with LADR 7, ~~complete~~by ~~all~~the ~~pre-IND~~end of ~~studies,~~2024 ~~and~~(the toperiod ~~obtain~~for the FDA review of an IND ~~could~~application beis ~~approximately~~30 $2days). ~~million~~If inthe ~~direct~~Company ~~costs,~~encounters ~~based~~difficulties onwith ~~current~~the toxicology ~~estimates,~~program ~~representing~~or afails ~~capital~~to meet the FDA’s requirements for the IND application, the first-~~efficient~~patient ~~path~~dosing tocould ~~clinical~~be ~~entry~~substantially delayed.

Because the LADR™ backbone in future products would be the same as the LADR™ backbone in current product candidates, (i.e. the chemotoxin can be changed without changing the LADR™ backbone), management anticipates that future product candidates beyond ~~LADR 7~~LADR7-10 may enjoy abbreviated pre-clinical pathways to first-in-human. Such abbreviated pathways would be subject to FDA review and agreement.

The Company’s novel companion diagnostic, ACDx™ (albumin companion diagnostic) was developed to identify patients with cancer who are most likely to benefit from treatment with the four LADR™ lead assets. We have not yet determined whether the use of a companion diagnostic will be necessary or helpful, and plan to continue to investigate this question in parallel to the pre-clinical and clinical development of LADRs 7-10.

The LADR™ backbone and drugs that employ LADR™ are protected by domestic and international patents, and additional patents are pending.

Business Strategy for LADR™ Platform

With the non-dilutive financing concluded with XOMA (as defined below) in June 2023, the Company is now focused on ~~commencing~~preparing the work ~~needed~~necessary to ~~submit~~file an IND application with the FDA for LADR7. ~~Specifically~~For example, the Company isrecently ~~working~~completed ~~with~~the ~~its~~production ~~vendors to initiate GMP manufacturing~~ of ~~LADR7, and~~approximately to100 ~~initiate the toxicology program that will form the basis~~ grams of ~~the IND for~~ LADR7. ~~Management~~under ~~estimates that the~~ GMP, ~~manufacture~~which ~~and IND-enabling~~is ~~toxicology~~sufficient ~~studies~~to ~~for~~carry ~~LADR7~~out ~~will~~final betoxicology ~~completed in the fourth quarter of 2024~~studies, ~~with~~and ~~submission of the IND~~ to ~~the~~initiate ~~FDA~~Phase ~~shortly thereafter.~~IA ~~Management~~studies ~~will continue to explore~~ in ~~parallel~~human ~~both partnered and non-partnered funding and development strategies for LADR™ with a goal of obtaining the least costly capital possible to enable value inflection milestones~~subjects.

The Company has also initiated the Good Laboratory Practices (“GLP”) toxicology program that is expected to form the foundation of the IND application for LADR 7 to the FDA. Management expects the toxicology studies to be completed and the IND application for LADR 7 to be filed with the FDA by the end of the third quarter of 2024 or the beginning of the fourth quarter of 2024. Absent a clinical hold from the FDA, this timeline should allow the Company to be ready for first-patient dosing with LADR 7 by the end of 2024 (the period for the FDA review of an IND application is 30 days). If the Company encounters difficulties with the toxicology program or fails to meet the FDA’s requirements for the IND, the first-patient dosing could be substantially delayed.

Management will continue to explore in parallel both partnered and non-partnered funding and development strategies for LADR™ with a goal of obtaining the least costly capital possible to enable value inflection milestones.

Partnering of Aldoxorubicin

On July 27, 2017, the Company entered into an exclusive worldwide license with ImmunityBio, Inc. ( the “2017 License Agreement”) (formerly known as NantCell, Inc., and which merged with NantKwest Inc. in March 2021 (“ImmunityBio”)), granting to ImmunityBio the exclusive rights to develop, manufacture and commercialize aldoxorubicin in all indications. As a result, we are no longer directly working on the development of aldoxorubicin. As part of the ~~license~~2017 ~~agreement~~License Agreement, ImmunityBio made a strategic investment of $13 million in in LadRx’s common stock at $660.00 per share (adjusted to reflect our ~~1-for-6~~ reverse stock ~~split effectuated in October 2017~~splits), a premium of 92% to the market price on that date. The Company also issued a warrant to ImmunityBio to purchase up to 5,000 shares of common stock at $660.00 per share, which such warrant expired on January 26, 2019.

ImmunityBio isconducted ~~conducting~~ an open-label, randomized, Phase 2 study of a combination of immunotherapy, aldoxorubicin, and standard-of-care chemotherapy versus standard-of-care chemotherapy alone for the treatment of locally advanced or metastatic pancreatic cancer in patients who have had 1 or 2 lines of treatment (Cohorts A and B) or 3 or greater lines of treatment (cohort C). In June 2022, Immunity Bio presented data at the American Society of Clinical Oncology meeting showing that patients receiving combination immunotherapy with aldoxorubicin plus standard-of-care chemotherapy experienced overall survival of 5.8 months, compared to 3 months for historical control patients that had received only the standard-of-care chemotherapy (n=78, 95% confidence interval of 4 to 6.9 months). An additional 25 patients in the experimental group remain in the study. ~~Thus~~As ~~far~~of the date of this Quarterly Report, there have been no treatment-related deaths, and serious adverse events have been uncommon (6%).

Aldoxorubicin has received Orphan Drug Designation (“ODD”) by the FDA for the treatment of soft tissue sarcoma (“STS”). ODD provides several benefits including seven years of market exclusivity after approval, certain R&D related tax credits, and protocol assistance by the FDA. European regulators granted aldoxorubicin Orphan designation for STS which confers ten years of market exclusivity among other benefits.

ImmunityBio also lists ongoing clinical studies in head and neck cancer and has submitted a protocol with the FDA for glioblastoma.

Royalty Purchase Agreement with XOMA

On June 21, 2023, the Company, entered into (i) a Royalty Purchase Agreement (the “Royalty Agreement”) with XOMA (US) LLC (“XOMA”), for the sale, transfer, assignment and conveyance of the Company’s right, title and interest in and to certain royalty payments and milestone payments with respect to aldoxorubicin, and (ii) an Assignment and Assumption Agreement (the “Assignment Agreement”) with XOMA for the sale, transfer, assignment and conveyance of the Company’s right, title and interest in the Asset Purchase Agreement (the “2011 Arimoclomol Agreement”) between the Company and Orphazyme ApS (“Orphazyme”), dated as of May 13, 2011, and assigned to Zevra Denmark A/S (“Zevra Denmark”), effective as of June 1, 2022, which includes certain royalty and milestone payments with respect to arimoclomol. The combined aggregate purchase price paid to the Company for the sale, transfer, assignment and conveyance of the Company’s right, title and interest in and to aldoxorubicin and arimoclomol was $5 million, less certain transaction fees and expenses.

~~Pursuant~~The toRoyalty Agreement and the ~~Royalty~~Assignment Agreement, ~~the~~also ~~Company~~provide ~~agreed~~for up to ~~sell,~~an ~~transfer,~~additional ~~assign~~$6 million based on regulatory and ~~convey~~commercial milestones related to ~~XOMA,~~the ~~among~~development ~~other~~of ~~payments~~arimoclomol and aldoxorubicin by their respective sponsors, ~~all~~Zevra, ~~royalty payments~~Inc. and ~~regulatory~~Immunity ~~and~~Bio. ~~commercial~~The ~~milestone~~$6 million in potential post-closing payments ~~payable~~is tocomprised ~~the~~of ~~Company~~$1 ~~pursuant~~million toupon acceptance by the ~~worldwide~~FDA ~~license~~of ~~agreement,~~the ~~dated July~~arimoclomol ~~27,~~New ~~2017~~Drug Application (“NDA”), $1 bymillion ~~and~~upon ~~between~~first ~~the~~commercial ~~Company~~sale of arimoclomol, and ~~Immunity~~$4 ~~Bio,~~million ~~Inc~~upon FDA approval of aldoxorubicin. ~~(formerly~~All ~~known~~royalty asand ~~NantCell,~~milestone ~~Inc.).~~payments made ~~The~~to ~~Royalty~~XOMA ~~Agreement~~will ~~also~~be ~~provides~~net ~~for~~of the ~~sharing~~existing oflicensing ~~certain~~and ~~rights with~~milestone ~~XOMA~~obligations owed by LadRx related to ~~bring~~arimoclomol ~~any~~and ~~action,~~aldoxorubicin. In ~~demand~~January 2024, ~~proceeding~~the orCompany ~~claim~~recognized asthe ~~related~~$1 million milestone relating to ~~receiving~~the ~~such~~acceptance ~~payments~~by the FDA of the arimoclomol NDA.

~~Management~~Pursuant ~~determined~~to ~~that~~ the Royalty Agreement, isthe ~~not~~Company ~~considered~~agreed to besell, ~~with~~transfer, aassign ~~customer~~and convey to XOMA, among other payments, all royalty payments and itregulatory ~~does~~and ~~not~~commercial ~~fall~~milestone ~~within~~payments payable to the ~~scope~~Company ofpursuant ~~ASC~~to ~~606. Instead,~~ the ~~Agreement~~worldwide ~~represents~~license anagreement, ~~in-substance~~dated ~~sale~~July of27, ~~nonfinancial assets~~2017, by and, ~~therefore, should~~between bethe ~~accounted~~Company ~~for~~and ~~within~~Immunity ~~the~~Bio. ~~scope of~~The ~~ASC~~Royalty ~~610-20.~~Agreement Asalso ~~such,~~provides for the ~~Company~~sharing ~~recognized~~of ~~such~~certain ~~net~~rights ~~proceeds~~with asXOMA ~~other~~to ~~income~~bring any inaction, ~~the~~demand, ~~accompanying~~proceeding ~~statement~~or ofclaim ~~operations~~as related to receiving such payments.

~~Transfer~~Management ofdetermined ~~Rights~~that the Royalty Agreement is not considered to ~~Molecular~~be ~~Chaperone~~with ~~Assets~~a customer, and it does not fall within the scope of ASC 606. Instead, the Royalty Agreement represents an in-substance sale of nonfinancial assets, and, therefore, should be accounted for within the scope of ASC 610-20. As such, the Company recognized such net proceeds as other income in the accompanying statement of operations.

Transfer of Rights to Molecular Chaperone Assets (Orphazyme)

On May 13, 2011, pursuant to the Asset Purchase Agreement by and between the Company and Orphazyme A/S (“Orphazyme”, formerly Orphazyme ApS), LadRx sold the rights to arimoclomol and iroxanadine, based on molecular chaperone regulation technology, in exchange for a one-time, upfront payment and the right to receive up to a total of $120 million in milestone payments upon the achievement of certain pre-specified regulatory and business milestones, as well as royalty payments based on a specified percentage of any net sales of products derived from arimoclomol (the “2011 Arimoclomol Agreement”). Orphazyme transferred its rights and obligations under the 2011 Arimoclomol Agreement to KemPharm Denmark A/S (“KemPharm”), a wholly owned subsidiary of KemPharm Inc., in May 2022.

In May 2021, Orphazyme announced that the pivotal phase 3 clinical trial for arimoclomol in Amyotrophic Lateral Sclerosis did not meet its primary and secondary endpoints, reducing the maximum amount that LadRx currently has the right to receive under the 2011 Arimoclomol Agreement to approximately $100 million. Orphazyme also tested arimoclomol in Niemann-Pick disease Type C (“NPC”) and Gaucher disease, and following a Phase II/III trial submitted to the FDA a ~~New~~NDA ~~Drug Application~~ for the treatment of NPC with arimoclomol. On June 18, 2021, Orphazyme announced it had received a complete response letter (the “Complete Response Letter”) from the FDA indicating the need for additional data. In late October 2021, Orphazyme announced it held a Type A meeting with the FDA, at which the FDA recommended that Orphazyme submit additional data, information and analyses to address certain topics in the Complete Response Letter and engage in further interactions with the FDA to identify a pathway to resubmission. The FDA concurred with Orphazyme’s proposal to remove the cognition domain from the NPC Clinical Severity Scale (“NPCCSS”) endpoint, with the result that the primary endpoint is permitted to be recalculated using the 4- domain NPCCSS, subject to the submission of additional requested information which Orphazyme had publicly indicated that it intended to provide. To bolster the confirmatory evidence already submitted, the FDA affirmed that it would require additional in vivo or pharmacodynamic (PD)/pharmacokinetic (PK) data.

Orphazyme had also submitted a Marketing Authorization Application (“MAA”) with the European Medicines Agency (the “EMA”). In February 2022, Orphazyme announced that although they had received positive feedback from the Committee for Medicinal Products for Human Use (“CHMP”) of the EMA, they were notified by the CHMP of a negative trend vote on the MAA for arimoclomol for NPC following an oral explanation.

On May 31, 2022, Orphazyme announced that it had completed the sale of substantially all of its assets and business activities for cash consideration of $12.8 million and assumption of liabilities estimated to equal approximately $5.2 million to KemPharm (the “KemPharm Transaction”). KemPharm is a specialty biopharmaceutical company focused on the discovery and development of novel treatments for rare CNS diseases. As part of the KemPharm Transaction, all of Orphazyme’s obligations to LadRx under the 2011 Arimoclomol Agreement, including with regard to milestone payments and royalties on sales, were assumed by KemPharm. KemPharm is expected to continue the early access programs with arimoclomol, and to continue to pursue the potential approval of arimoclomol as a treatment option for NPC. KemPharm ~~indicated~~resubmitted ~~it plans on resubmitting~~ the NDA for arimoclomol in 2023, and in January 2024, the FDA accepted KenPharm’s NDA. ItKenPharm is also identifying a regulatory path forward with the EMA. KemPharm re-branded to Zevra Therapeutics, Inc. in February 2023.

Assignment and Assumption Agreement with XOMA

On June 21, 2023, the Company entered into the Assignment Agreement with XOMA, pursuant to which, among others, the Company agreed to sell, transfer and assign to XOMA the Company’s right, title and interest in the arimoclomol pursuant to the 2011 Arimoclomol Agreement, including the right to receive certain milestone, royalty and other payments from Zevra.

Pursuant to the Assignment Agreement, the Company is entitled to receive (i) a one-time payment of $1 million upon acceptance of a re-submission of a ~~New~~NDA ~~Drug Application~~ to the FDA for arimoclomol, which the Company received in February 2024, and (ii) a one-time payment of $1 million upon the first invoiced sale in certain territories of a pharmaceutical product derived from arimoclomol as an active pharmaceutical ingredient, subject to the receipt of the applicable regulatory approval required to sell such a product in such countries.

Critical Accounting Policies and Estimates

Management’s discussion and analysis of our financial condition and results of operations are based on our financial statements, which have been prepared in accordance with accounting principles generally accepted in the UUnited States.S. The preparation of these financial statements requires ~~management~~ management to make estimates and judgments that affect the reported amounts of assets, liabilities, revenue and expenses, and related ~~disclosure~~ disclosure of contingent assets and liabilities. On an ongoing basis, management evaluates its estimates, including those related to revenue recognition, impairment of long-lived assets, including finite-lived intangible assets, research and development expenses and clinical trial expenses and stock-based compensation expense.

We base our estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ materially from these estimates under different assumptions or conditions.

Our significant accounting policies ~~and discussion of recently issued accounting pronouncements~~ are summarized in Note 2 to our audited ~~consolidated~~ financial statements contained in ~~the~~our ~~Annual~~2023 ~~Report on Form 10-K for the year ended December 31, 2022 (“the 2022~~ Annual Report”).

We believe the following critical accounting policies affect our more significant judgments and estimates used in the preparation of our financial statements.

Stock-Based Compensation

The Company accounts for share-based awards to employees and nonemployees directors and consultants in accordance with the provisions of ASC 718, Compensation—Stock Compensation., and under the recently issued guidance following FASB’s pronouncement, ASU 2018-07, Compensation—Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting. Under ASC 718, and applicable updates adopted, share-based awards are valued at fair value on the date of grant and that fair value is recognized over the requisite service, or vesting, period. The Company values its equity awards using the Black-Scholes option pricing model, and accounts for forfeitures when they occur.

Known Trends, Events, and Uncertainties

In May 2023, the World Health Organization determined that COVID-19 no longer fit the definition of a public health emergency and the declaration of a public health emergency associated with COVID-19 subsequently expired on May 11, 2023. COVID-19 is expected to remain a serious endemic threat for an indefinite future period and has adversely affected and may continue to adversely affect our operations and global economy. The Company does not believe that inflation has had a material effect on its operations to date, other than the impact of inflation on the general economy. However, there is a risk that the Company’s operating costs could become subject to inflationary pressures in the future, which would have the effect of increasing the Company’s operating costs, and which would put additional stress on the Company’s working capital resources.

Additionally, the consequences of the ongoing conflict between Russia and Ukraine, and the ongoing conflict between Israel and Hamas, including related sanctions and countermeasures, are difficult to predict, and could adversely impact geopolitical and macroeconomic conditions, the global economy, and contribute to increased market volatility, which may in turn adversely affect our business and operations. Furthermore, other than as discussed in this report, we have no committed source of financing and may not be able to raise money as and when we need it to continue our operations. If we cannot raise funds as and when we need them, we may be required to severely curtail, or even to cease, our operations. Other than as discussed above and elsewhere in this report, we are not aware of any trends, events or uncertainties that are likely to have a material effect on our financial condition.

The Company does not believe that inflation has had a material effect on its operations to date, other than the impact of inflation on the general economy. However, there is a risk that the Company’s operating costs could become subject to inflationary pressures in the future, which would have the effect of increasing the Company’s operating costs, and which would put additional stress on the Company’s working capital resources.

Additionally, the consequences of the ongoing conflict between Russia and Ukraine, and the ongoing conflict between Israel and Hamas, including related sanctions and countermeasures, are difficult to predict, and could adversely impact geopolitical and macroeconomic conditions, the global economy, and contribute to increased market volatility, which may in turn adversely affect our business and operations. Furthermore, other than as discussed in this Quarterly Report, we have no committed source of financing and may not be able to raise money as and when we need it to continue our operations. If we cannot raise funds as and when we need them, we may be required to severely curtail, or even to cease, our operations. Other than as discussed above and elsewhere in this report, we are not aware of any trends, events or uncertainties that are likely to have a material effect on our financial condition.

Liquidity and Capital Resources

Going Concern

The Company’s condensed ~~consolidated~~ financial statements have been presented on the basis that it will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. During the ~~nine~~three-month ~~months~~ period ended ~~September 30~~March 31, ~~2023~~2024, although ~~the~~we ~~Company~~ realized a net income of $10.2 million,~~258,479,~~ itwe had a loss from operations of $20.8 million,~~941,517~~ and anincurred ~~accumulated~~a ~~deficit~~net loss from operations of $~~487~~3.8 million for the year ended December 31,~~647~~ 2023,~~995~~ and had total stockholders’ equity as of ~~September~~March 3031, ~~2023.~~2024 Inof ~~addition,~~$0.3 million. ~~the~~The Company has no recurring revenue, and we are likely to continue to incur losses unless and until we conclude a successful strategic partnership or financing for our LADR™ technology. As a result, management has concluded that there is substantial doubt about the Company’s ability to continue as a going concern. The Company’s ~~consolidated~~ financial statements do not include any adjustments that might result from the outcome of this uncertainty. The Company’s independent registered public accounting firm, in its report on the Company’s consolidated financial statements for the year ended December 31, ~~2022~~2023, has also expressed substantial doubt about the Company’s ability to continue as a going concern.

Net cash ~~provided~~used byin operating activities for the ~~nine~~three months ended ~~September~~March 3031, 2023 was $10.97 million, which was primarily the result of ~~the~~ ~~sale~~a ~~of royalty and milestone rights,~~ net loss offrom ~~transaction~~operations ~~costs~~ of $41.21 million, ~~less~~and a net ~~loss~~neutral ~~from~~in ~~operations~~net ofcash ~~$2.9~~outflows ~~million,~~associated ~~and $0.6~~with ~~million~~changes in ~~net~~assets and liabilities. The net cash ~~inflows~~outflows associated with changes in assets and liabilities were primarily due to a decrease of $0.2 million of prepaid expenses and other current assets and an increase $0.2 million of accounts payable.

~~Net~~There ~~cash~~were ~~used~~no ininvesting ~~operating~~ activities ~~for~~in ~~the~~either ~~nine~~of ~~months ended September 30, 2022 was $3.3 million, which was primarily~~ the ~~result~~three-month ofperiods ~~a net~~ended ~~loss~~March ~~from operations of $3.3 million~~31, ~~and~~2024 ~~a net neutral in net cash outflows associated with changes in assets~~ and ~~liabilities. The net cash outflows associated with changes in assets and liabilities were primarily due to decreases of $1.2. million of prepaid expenses and other current assets~~2023, ~~$0.2 million of insurance claim receivable~~ and ~~$0.1~~we ~~million~~do ofnot ~~amortization~~expect ofany ~~right-of-use asset, offset by~~significant ~~reductions~~capital ofspending ~~$0.5~~during ~~million~~the ofnext ~~accounts~~12 ~~payable, $0~~months.~~9 million in accrued liabilities and $0.1 million of decrease in lease liabilities.~~

WeThere ~~purchased~~were ~~minimal~~no ~~fixed~~financing ~~assets~~activities in ~~both~~ the ~~nine~~three-month ~~periods~~period ended ~~September~~March 3031, ~~2023~~2024, ~~and~~whereas ~~September~~we ~~30,~~paid ~~2022,~~dividends ~~and~~on dothe ~~not~~shares ~~expect~~of ~~any~~Series C 10.00% ~~significant~~Convertible ~~capital~~Preferred ~~spending~~Stock ~~during~~of $0.1 million in the ~~next~~three-month 12period ~~months~~ended March 31, 2023.

We purchased the preferred investment options for $250,000 and paid dividends on the shares of Series C Preferred Stock of $69,000 in the nine-month period ended September 30, 2023; we paid dividends on the shares of Series C Preferred Stock of $0.5 million in the same period in 2022.

We continue to evaluate potential future sources of capital, as we do not currently have commitments from any third parties to provide us with additional capital and we may not be able to obtain future financing on favorable terms, or at all. The results of our technology licensing efforts and the actual proceeds of any fund-raising activities will determine our ongoing ability to operate as a going concern. Our ability to obtain future financings through joint ventures, product licensing arrangements, royalty sales, equity financings, grants or otherwise is subject to market conditions and our ability to identify parties that are willing and able to enter into such arrangements on terms that are satisfactory to us. Depending upon the outcome of our fundraising efforts, the accompanying financial information may not necessarily be indicative of our future financial condition. Failure to obtain adequate financing would adversely affect our ability to operate as a going concern.

We do not have any off-balance sheet arrangements.

23There can be assurance that we will be able to generate revenues from our product candidates and become profitable. Even if we become profitable, we may not be able to sustain that profitability.

There can be no assurance that we will be able to generate revenues from our product candidates and become profitable. Even if we become profitable, we may not be able to sustain that profitability.

Results of Operations

We recorded a net ~~income (~~loss) from operations of approximately $(0.8) million ~~and $1.3 million~~ for the three-month ~~and~~period ~~nine-month periods~~ ended ~~September 30,~~March ~~2023~~31, ~~respectively~~2024, as compared to a net loss of approximately $1.21 million ~~and $3.3 million~~ for the three-month ~~and~~period ~~nine-month periods~~ ended ~~September~~March 3031, ~~2022, respectively~~2023.

We recognized no licensing revenue in the nine-month periods ended September 30, 2023 and 2022. We will no longer be entitled to future licensing revenues from our current licensing agreements, since we transferred the royalty and milestone rights associated with arimoclomol and aldoxorubicin to XOMA, pursuant to the Royalty Purchase Agreement and the Assignment Agreement for net proceeds of approximately $4.2 million, along with an aggregate of $6 million in potential post-closing payments, based on achievement of certain future milestones. We recognized the net proceeds in connection with the Royalty Purchase Agreement and the Assignment Agreement as Other Income on our condensed consolidated statement of operations.19

During the three-month periods ended March 31, 2024 and 2023, we recognized no service revenue and earned an immaterial amount of license fees and grant revenue. We will no longer be entitled to future licensing revenues from our current licensing agreements, since we transferred the royalty and milestone rights associated with arimoclomol and aldoxorubicin to XOMA, pursuant to the Royalty Agreement and the Assignment Agreement for net proceeds of approximately $4.2 million, along with an aggregate of $6 million in potential post-closing payments, based on achievement of certain future milestones. We received a gross payment of $1 million milestone from this agreement in the period ended March 31, 2024, which we recognized as Other Income on our statement of operations.

General and Administrative Expenses

	Three-Month Period Ended September 30,				Nine-Month Period Ended September 30,
	Three-Month Period Ended March 31,
	2023		2022		2023		2022
	2024		2023
	(In thousands)				~~(In thousands)~~
General and administrative expenses	$	~~823~~749	$	1,~~161~~077	$	~~2,918~~	$	~~3,590~~
Amortization of stock awards		—51		3—		—		9
Depreciation and amortization		32		43		9		11
	$	~~826~~802	$	1,~~168~~080	$	~~2,927~~	$	~~3,610~~

General and administrative expenses include all administrative salaries and general corporate expenses, including legal expenses. Our general and administrative expenses, excluding stock ~~expense~~expenses, non-cash expenses and depreciation and amortization, were $0.87 million ~~and $2.9 million~~ for the three ~~and nine~~-month ~~periods~~period ended ~~September~~March 3031, ~~2023~~2024, ~~respectively,~~ and $1.21 million ~~and $3.6 million, respectively,~~ for the same ~~periods~~period in ~~2022~~2023. Our general and administrative expenses in the comparative periods excluding amortization of stock awards, non-cash expenses and depreciation and amortization, decreased ~~marginally~~primarily due to a decrease in professional fees and insurance costs, offset by an increase in franchise taxes.

Depreciation and Amortization

Depreciation expense reflects the depreciation of our equipment and furnishings.

Forgiveness of Accounts Payable

During the nine-month period ended September 30, 2022, one of the Company’s vendors issued a credit note of $353,565 related to past general and administrative services. No such credit note was recognized in the nine-month period ended September 30, 2023.

Interest Income

Interest income was approximately $2418,~~000~~600 ~~and $31,000~~ for the three-month ~~and~~period ~~nine-month periods~~ ended ~~September~~March 3031, ~~2023~~2024, ~~respectively,~~ as compared to $14,~~000~~300 ~~and $3,000, respectively,~~ for the same ~~periods~~period in ~~2022~~2023.

Item 3. — Quantitative and Qualitative Disclosures About Market Risk

Our exposure to market risk is limited primarily to interest income sensitivity, which is affected by changes in the general level of U.S. interest rates, particularly because a significant portion of our investments are in short-term debt securities issued by the U.S. government and institutional money market funds. The primary objective of our investment activities is to preserve principal. Due to the nature of our short-term investments, we believe that we are not subject to any material market risk exposure. We do not have any speculative or hedging derivative financial instruments or foreign currency instruments. If interest rates had varied by 10% in the three-month period ended ~~September~~March 3031, ~~2023~~2024, it would not have had a material effect on our results of operations or cash flows for that period.

Item 4. — Controls and Procedures

Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our Chief Executive Officer and our Chief Financial Officer, performed an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Securities Exchange Act Rule 13a-15(e)) as of the end of the quarterly period covered by this Quarterly Report on Form 10-Q. Based on that evaluation, our Chief Executive Officer and our Chief Financial Officer concluded that our disclosure controls and procedures were effective to ensure that information required to be disclosed by us in reports that we file or submit under the Securities Exchange Act of 1934, as amended, is recorded, processed, ~~summarized~~ summarized and reported within the time periods specified in the rules and forms of the SEC.

Our disclosure controls and procedures are designed to provide reasonable assurance of achieving their objectives as specified above. Management does not expect, however, that our disclosure controls and procedures will prevent or detect all errors and fraud. Any control system, no matter how well designed and operated, is based upon certain assumptions and can provide only reasonable, not absolute, assurance that its objectives will be met. Further, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, within the Company have been detected.

Changes in Controls over Financial Reporting

There was no change in our internal control over financial reporting that occurred during the quarter ended ~~September~~March 3031, ~~2023~~2024 that materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. We continually seek to assure that all of our controls and procedures are adequate and effective. Any failure to implement and maintain improvements in the controls over our financial reporting could cause us to fail to meet our reporting obligations under the SEC’s rules and regulations. Any failure to improve our internal controls to address the weaknesses we have identified could also cause investors to lose confidence in our reported financial information, which could have a negative impact on the trading price of our common stock.

PART II — OTHER INFORMATION

Item 1. — Legal Proceedings

~~The Company is occasionally involved in legal proceedings and other matters arising from the normal course of business~~None. On November 30, 2022, Jerald Hammann (“Hammann”) filed a complaint (the “Complaint”) against the Company, Mr. Caloz, and Mr. Kriegsman (together, “Defendants”) in the Court of Chancery of the State of Delaware, alleging various violations of a Cooperation Agreement, dated August 21, 2020, by and between the Company and Hammann. The Complaint alleges breaches of a provision limiting the Board’s ability to effect discretionary compensation and a non-disparagement provision. The Complaint further alleges a breach of a purported implied obligation that the Company disclose various internal records to Hammann. Defendants have moved to dismiss the Complaint in its entirety. Hammann has opposed the motion to dismiss and briefing of the motion is ongoing. Defendants intend to litigate vigorously against Hammann’s claims. A hearing is scheduled for December 2023.

Item 1A. — Risk Factors

You should carefully consider and evaluate the information in this Quarterly Report and the risk factors set forth under the caption “Item 1A. Risk Factors” in our ~~2022~~2023 Annual Report, which was filed with the SEC on March 1627, ~~2023~~2024. The risk factors associated with our business have not materially changed compared to the risk factors disclosed in the ~~2022~~2023 Annual Report.

Item 2. — Unregistered Sales of Equity Securities and Use of Proceeds

None.

Item 3. —- Defaults Upon Senior Securities

None.

Item 4. —- Mine Safety Disclosure

Not applicable.

Item 5. —- Other Information

None.

Item 6. — Exhibits

The exhibits listed in the accompanying Index to Exhibits are filed ~~or furnished~~ as part of this Quarterly Report on Form 10-Q and incorporated ~~herein~~ herein by reference.

2521

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	LadRx Corporation
Date: November 14, 2023	By:	/s/ JOHN Y. CALOZ
Date: May 15, 2024	By:	/s/ JOHN Y. CALOZ
		John Y. Caloz
		Chief Financial Officer
		(Principal Financial and Accounting Officer)

2622

INDEX TO EXHIBITS

Exhibit Number		Description
3.1		Certificate of Amendment of Restated Certificate of Incorporation of LadRx Corporation (incorporated by reference to Exhibit 3.1 to the Company’s Form 8-K filed with the SEC on September 11, 2023).
31.1*		Certification of Chief Executive Officer pursuant to Rule 13A-14(a) or 15D-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
3.2		Amendments to the By-Laws of LadRx Corporation (incorporated by reference to Exhibit 3.2 to the Company’s Form 8-K filed with the SEC on September 11, 2023).
31.2*		Certification of Chief Financial Officer pursuant to Rule 13A-14(a) or 15D-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
10.1		Amendment No. 1 to the LadRx Corporation 2019 Stock Incentive Plan (incorporated by reference to Exhibit 10.1 to the Company’s Form 8-K filed with the SEC on September 11, 2023.
31.1*		Certification of Chief Executive Officer pursuant to Rule 13A-14(a) or 15D-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2*		Certification of Chief Financial Officer pursuant to Rule 13A-14(a) or 15D-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1**		Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
32.2**		Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101.INS		Inline XBRL Instance Document
101.SCH		Inline XBRL Schema Document
101.CAL		Inline XBRL Calculation Linkbase Document
101.DEF		Inline XBRL Definition Linkbase Document
101.LAB		Inline XBRL Label Linkbase Document
101.PRE		Inline XBRL Presentation Linkbase Document
104		Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

● * Filed herewith. ● Furnished herewith.

** Furnished herewith.23

Filing Compare · LadRx Corp